Autoimmune disease
MONDO:0007179A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to their own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).
Also known as: autoimmune disease, autoimmune disease or disorder, autoimmune disorder, disease, autoimmune, autoimmune hypersensitivity disease, hypersensitivity reaction type II disease
4033 clinical trials for this condition and its sub-types, 313 tagged with Autoimmune disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Autoimmune disease
-
Autoimmune disorder of the nervous system 47 trials · 1,060 incl. sub-types
4 sub-types
- Autoimmune disorder of central nervous system 2 trials · 874 incl. sub-types Sub-types →
- Autoimmune disorder of peripheral nervous system 0 trials · 194 incl. sub-types Sub-types →
- Pediatric acute-onset neuropsychiatric syndrome 8 trials · 10 incl. sub-types Sub-types →
- Autoimmune retinopathy 0 trials
-
Autoimmune disorder of gastrointestinal tract 0 trials · 936 incl. sub-types
7 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Celiac disease 79 trials Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune enteropathy 2 trials · 11 incl. sub-types Sub-types →
- Autoimmune gastritis 3 trials
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related sclerosing cholangitis 0 trials
-
Autoimmune disorder of endocrine system 1 trial · 925 incl. sub-types
13 sub-types
- Type 1 diabetes mellitus 815 trials · 816 incl. sub-types Sub-types →
- Autoimmune thyroid disease 8 trials · 62 incl. sub-types Sub-types →
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Autoimmune polyendocrinopathy 3 trials · 11 incl. sub-types Sub-types →
- Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome 10 trials
- Autoimmune hypoparathyroidism 0 trials · 8 incl. sub-types Sub-types →
- Autoimmune pancreatitis 3 trials Sub-types →
- Autoimmune primary ovarian failure 1 trial
- IgG4-related sclerosing cholangitis 0 trials
- Autoimmune enteropathy and endocrinopathy - susceptibility to chronic infections syndrome 0 trials
- Autoimmune oophoritis 0 trials
- Insulin autoimmune syndrome 0 trials
- Primary hypophysitis 0 trials Sub-types →
-
CNS demyelinating autoimmune disease 5 trials · 853 incl. sub-types
1 sub-type
- Multiple sclerosis 765 trials · 852 incl. sub-types Sub-types →
-
Autoimmune disorder of musculoskeletal system 0 trials · 795 incl. sub-types
3 sub-types
- Rheumatoid arthritis 576 trials · 795 incl. sub-types Sub-types →
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Neonatal dermatomyositis 0 trials
-
Lupus erythematosus 39 trials · 548 incl. sub-types
3 sub-types
- Systemic lupus erythematosus 516 trials · 522 incl. sub-types Sub-types →
- Cutaneous lupus erythematosus 38 trials · 46 incl. sub-types Sub-types →
- Drug-induced lupus erythematosus 1 trial
-
Scleroderma 47 trials · 305 incl. sub-types
3 sub-types
- Systemic sclerosis 261 trials · 295 incl. sub-types Sub-types →
- Localized scleroderma 14 trials · 15 incl. sub-types Sub-types →
- Neonatal scleroderma 0 trials
-
Autoimmune disorder of exocrine system 0 trials · 196 incl. sub-types
3 sub-types
- Sjogren syndrome 166 trials
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Benign lymphoepithelial lesion of salivary gland 0 trials
-
Autoimmune disorder of blood 0 trials · 152 incl. sub-types
2 sub-types
- Primary thrombocytopenia 27 trials · 110 incl. sub-types Sub-types →
- Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types Sub-types →
-
Autoimmune thrombocytopenia 8 trials · 113 incl. sub-types
2 sub-types
- Autoimmune thrombocytopenic purpura 95 trials
- Evans syndrome 19 trials
-
Vitiligo 100 trials
3 sub-types
- Generalized vitiligo 16 trials
- Alopecia universalis onychodystrophy vitiligo 0 trials
- Trichrome vitiligo 0 trials
-
Antiphospholipid syndrome 58 trials · 59 incl. sub-types
4 sub-types
- Primary antiphospholipid syndrome 4 trials
- Catastrophic antiphospholipid syndrome 1 trial
- Familial antiphospholipid syndrome 0 trials
- Secondary antiphospholipid syndrome 0 trials Sub-types →
-
Autoimmune bullous skin disease 7 trials · 55 incl. sub-types
11 sub-types
- Pemphigus 20 trials · 27 incl. sub-types Sub-types →
- Bullous pemphigoid 18 trials
- Mucous membrane pemphigoid 5 trials · 9 incl. sub-types Sub-types →
- Acquired epidermolysis bullosa 3 trials
- Dermatitis herpetiformis 1 trial Sub-types →
- Pemphigoid 1 trial
- IgA pemphigus 0 trials
- Anti-p200 pemphigoid 0 trials
- Linear IgA Dermatosis 0 trials
- Paraneoplastic pemphigus 0 trials
- Subcorneal pustular dermatosis 0 trials
-
Immunoglobulin G4-related sclerosing disease 30 trials · 34 incl. sub-types
14 sub-types
- Autoimmune pancreatitis 3 trials Sub-types →
- IgG4-related kidney disease 1 trial
- IgG4-related retroperitoneal fibrosis 1 trial Sub-types →
- IgG4-related aortitis 0 trials
- IgG4-related mediastinitis 0 trials
- IgG4-related mesenteritis 0 trials
- IgG4-related ophthalmic disorder 0 trials Sub-types →
- IgG4-related pachymeningitis 0 trials
- IgG4-related sclerosing cholangitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- IgG4-related thyroid disease 0 trials
- Cutaneous pseudolymphoma 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
- Primary cutaneous plasmacytosis 0 trials
-
Rheumatic fever 16 trials
-
Overlapping connective tissue disease 2 trials · 15 incl. sub-types
2 sub-types
- Mixed connective tissue disease 15 trials
- MASS syndrome 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
Type III hypersensitivity disease 3 trials · 6 incl. sub-types
2 sub-types
- Serum sickness 3 trials
- Arthus reaction 0 trials
-
Autoimmune disease of ear, nose and throat 0 trials · 4 incl. sub-types
7 sub-types
- Autoimmune inner ear disease 2 trials
- Autoimmune uveitis 2 trials
- Cogan syndrome 0 trials
- IgG4-related dacryoadenitis and sialadenitis 0 trials
- IgG4-related submandibular gland disease 0 trials
- Autoimmune retinopathy 0 trials
- Eosinophilic angiocentric fibrosis 0 trials
-
Cryoglobulinemia 3 trials
1 sub-type
- Cryofibrinogenemia 0 trials Sub-types →
-
Autoimmune disorder of cardiovascular system 0 trials · 3 incl. sub-types
6 sub-types
- Chilblain lupus 1 trial · 3 incl. sub-types Sub-types →
- Libman-Sacks endocarditis 0 trials
- Autoimmune atherosclerosis 0 trials
- Autoimmune cardiomyopathy 0 trials Sub-types →
- Autoimmune vasculitis 0 trials Sub-types →
- Rheumatic pulmonary valve disease 0 trials
-
Susac syndrome 2 trials
-
Autoimmune disease, multisystem, infantile-onset 0 trials · 2 incl. sub-types
-
Phacolytic glaucoma 1 trial
-
Secondary neonatal autoimmune disease 0 trials · 1 incl. sub-types
6 sub-types
- Neonatal lupus erythematosus 1 trial
- Neonatal antiphospholipid syndrome 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
- Neonatal dermatomyositis 0 trials
- Neonatal scleroderma 0 trials
- Transient neonatal myasthenia gravis 0 trials
-
Jaccoud syndrome 0 trials
-
Kimura disease 0 trials
-
Reynolds syndrome 0 trials
-
Autoimmune glomerulonephritis 0 trials
-
Autoimmune urticaria 0 trials
-
Euthyroid Graves orbitopathy 0 trials
-
Tempi syndrome 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 726 trials in this tab.
-
Real-World lupus drug study launches in poland
Disease control OngoingThis study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug riliprubart tested for Long-Term control of nerve disease CIDP
Disease control By invitation onlyThis study is a long-term extension of earlier trials testing the drug riliprubart in adults with CIDP, a condition where the immune system attacks the nerves, causing weakness and numbness. About 300 participants who completed a prior riliprubart study will continue receiving th…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in large trial
Disease control By invitation onlyThis study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for lupus skin lesions: drug trial targets stubborn cases
Disease control OngoingThis study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…
Phase 2/3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gene therapy shot aims to tame autoimmune diseases in early trial
Disease control OngoingThis early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…
Early phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New daily pill could rival infusion for slowing progressive MS
Disease control OngoingThis phase 3 trial compares two drugs for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens. About 985 adults with PPMS will receive either daily oral fenebrutinib or intravenous ocrelizumab (plus matching placebos) to see which better delays disab…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New MS pill aims to outperform current treatment
Disease control OngoingThis Phase 3 study compares fenebrutinib, an experimental oral drug, to teriflunomide, an approved MS therapy, in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take eit…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New AI-Powered insulin system could free people with diabetes from constant meal calculations
Disease control OngoingThis study tests AIDANET, an automated insulin delivery algorithm, in 40 adults with type 1 diabetes. Participants will use the system in three modes: fully automatic (no meal announcements), hybrid (with meal announcements), or a mix. The goal is to see which mode keeps blood su…
Sponsor: Sue Brown • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Immune cell therapy takes on tough scleroderma
Disease control OngoingThis early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The stu…
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a skin cream bring back color to faces with vitiligo?
Disease control OngoingResearchers are testing a cream called delgocitinib on facial vitiligo, a condition where skin loses its color in patches. Twelve adults with non-segmental vitiligo on the face will apply the cream twice daily for 24 weeks. The trial measures changes in the size and severity of w…
Phase 2 • Sponsor: Lone Skov • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill aims to tame rare immune diseases
Disease control OngoingThis early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill could tame lupus flares in major trial
Disease control OngoingThis phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New app helps teens with diabetes focus on what they do well
Disease control OngoingThis study tests a program called 'Type 1 Doing Well' for youth aged 10–13 with type 1 diabetes and their parents. The program uses a smartphone app, goal-setting, and family meetings to build on the teen's diabetes strengths. Researchers want to see if it improves blood sugar co…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New MS drug candidate enters early safety testing
Disease control OngoingThis early-stage study is testing a new drug called RO7121932 in 129 people with multiple sclerosis (MS). The goal is to check if the drug is safe and how the body handles it when given as a single or multiple doses, either through a vein or under the skin. Participants are not o…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a daily ultrasound zap arthritis pain at home?
Disease control OngoingThis study tests a non-invasive device that uses ultrasound to stimulate the spleen and reduce inflammation in people with moderate to severe rheumatoid arthritis. About 60 adults who haven't responded well to standard medications will use the device at home for 12 weeks, with so…
Sponsor: SecondWave Systems Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Robot-Assisted surgery for lung cancer and thymus disease put to the test
Disease control OngoingThis study is testing a new robotic surgery system, the da Vinci SP, for removing part or all of a lung (lobectomy) or the thymus gland (thymectomy) in people with lung cancer, benign lung disease, thymoma, or myasthenia gravis. The goal is to see if the robot can perform these s…
Sponsor: Intuitive Surgical • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Investigational drug AMG 335 offered to adults with IgG4-Related disease
Disease control ApprovedThis expanded access program allows adults with a confirmed diagnosis of IgG4-related disease to request the investigational drug AMG 335, also known as UPLIZNA. IgG4-related disease is a rare condition where the immune system causes inflammation and swelling in organs. The progr…
Sponsor: Amgen • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New MS drug trial targets kids: could ocrelizumab slow relapses?
Disease control OngoingThis study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Blood-Cleaning device hit its plasma exchange targets?
Disease control OngoingResearchers review past therapeutic plasma exchange treatments performed with the multiFiltratePRO, a device that cleans blood outside the body. The study looks at records from people with autoimmune diseases who weighed at least 40 kg and received this treatment between 2019 and…
Sponsor: Fresenius Medical Care Deutschland GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug hope for kids with rare Muscle-Weakening disease
Disease control OngoingThis study tests a drug called rozanolixizumab in 12 children aged 2 to 18 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive injections, and resea…
Phase 2/3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for rare blood disorder: drug trial targets anemia
Disease control OngoingThis phase 3 trial tests a drug called ianalumab against a placebo in 90 adults with warm autoimmune hemolytic anemia (wAIHA) who have already tried at least one treatment without success. The goal is to see if ianalumab can raise hemoglobin levels and keep them stable for at lea…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New stem cell transplant trial aims to control tough lymphoma
Disease control OngoingThis study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control By invitation onlyThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…
Phase 3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
Disease control OngoingResearchers are testing whether deucravacitinib, a daily oral drug, can reduce joint swelling, tenderness, and skin symptoms in people with active psoriatic arthritis. The trial enrolls adults who have not taken biologic drugs for their arthritis or who previously received a TNF …
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New lupus drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for ITP patients: experimental drug aims to boost platelets
Disease control OngoingThis phase 2 trial tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants have already tried steroids and another standard treatment. The study mea…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThis Phase 3 study tests whether anifrolumab, given as a weekly shot, can improve symptoms of systemic sclerosis (scleroderma) compared to a placebo. About 314 adults aged 18-70 with early-stage disease will take part. The main goal is to see if more people respond to treatment, …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New weekly shot aims to tame Sjögren's Flare-Ups
Disease control OngoingThis study tests an experimental drug called IMVT-1402 in 180 adults with moderate to severe Sjögren's disease. Participants receive either the drug or a placebo as a weekly injection under the skin for 24 weeks. The goal is to see if the drug can reduce overall disease activity …
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could stem cell islets end daily insulin shots?
Disease control OngoingThis early-phase trial tests VX-264, a therapy made from stem cells that produce insulin, in 7 people with long-standing type 1 diabetes. The goal is to see if it is safe and can help control blood sugar. If successful, it may reduce or replace the need for insulin injections.
Phase 1/2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New injection aims to tame lupus when standard treatments fail
Disease control OngoingThis early-stage study tests an injection called GC012F in 20 adults with refractory systemic lupus erythematosus (SLE) — a type of lupus that hasn't responded to standard treatments. The goal is to see if the therapy is safe and can reduce disease activity. Participants receive …
Phase 1/2 • Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New arthritis drug shows promise in Long-Term safety trial
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with psoriatic arthritis. About 1560 adults who finished an earlier study will receive the drug as a shot under the skin. Researchers will track side effects and how well the drug c…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New insulin icodec study aims to improve diabetes control
Disease control OngoingThis study observes how well insulin icodec controls blood sugar in 245 people with type 1 diabetes who have never used it before. Participants take the insulin as prescribed by their doctor, and researchers track changes in HbA1c and treatment satisfaction over about 22 to 30 we…
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take on rare autoimmune disease in kids
Disease control PausedThis early-stage trial tests whether a type of immunotherapy called CAR-T cells can safely treat children with severe systemic sclerosis, a rare autoimmune disease that causes skin thickening and organ damage. The treatment involves collecting the child's own immune cells, engine…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a short pill course save hand function in advanced MS?
Disease control OngoingThis UK trial tests whether cladribine tablets, taken for just 8-10 days a year over two years, can slow the loss of hand function in people with advanced multiple sclerosis (MS). The study includes 204 participants with significant disability (EDSS 6.5-8.5). Half receive cladrib…
Phase 2/3 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
CAR-T cells take on progressive MS: early trial launches
Disease control OngoingThis early-phase trial tests a single dose of YTB323, a CAR-T cell therapy, in 28 adults with non-active progressive multiple sclerosis. The study aims to check safety and track disability changes over time. Participants must be 18–60 and able to undergo lumbar punctures and MRIs…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Lupus drug anifrolumab put to the test in Real-World study
Disease control OngoingThis study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Engineered immune cells take on tough Muscle-Weakening disease
Disease control OngoingThis early-stage trial is testing a new treatment called YTB323 for people with generalized myasthenia gravis that hasn't responded to standard therapies. YTB323 is a CAR-T cell therapy, meaning a patient's own immune cells are modified in a lab to better attack the disease. The …
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
Disease control OngoingThis early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New lupus drug RO7507062 enters first human safety trial
Disease control OngoingThis early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug GS-0151 tested for rheumatoid arthritis in early trial
Disease control OngoingThis early-stage trial is testing a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either GS-0151 or a placebo for 12 weeks.
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new knee implant design offer better Long-Term relief?
Disease control By invitation onlyThis study tests a new total knee replacement system called LinkSymphoKnee, which uses an ultra-congruent bearing surface designed to provide stability and mimic natural knee movement. Researchers will enroll 600 adults aged 18 to 79 who need a knee replacement due to osteoarthri…
Sponsor: LinkBio Corp. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug CND261 tested for rheumatoid arthritis relief
Disease control OngoingThis early-stage study tests a new drug, CND261, in 47 adults with moderate to severe rheumatoid arthritis who haven't responded well to other treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that it might…
Phase 1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cell therapy YTB323 targets MS that breaks through strongest drugs
Disease control OngoingThis early-phase study tests an experimental cell therapy called YTB323 in about 28 people with relapsing multiple sclerosis whose disease is still active despite taking strong medications. The goal is to see if YTB323 is safe and can control the disease. Participants receive a s…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can these pills save Insulin-Making cells in newly diagnosed type 1 diabetes?
Disease control OngoingThis phase 2 trial tests two oral drugs, abrocitinib and ritlecitinib, in 78 people aged 12-35 who were diagnosed with type 1 diabetes within the last 100 days. The goal is to see if these JAK inhibitors can help preserve the body's ability to produce insulin, measured by a stimu…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug hope for scleroderma patients with lung complications
Disease control OngoingThis study tests an experimental drug called ifetroban in 34 adults with a severe form of scleroderma (diffuse cutaneous systemic sclerosis) or scleroderma-related lung disease (pulmonary arterial hypertension). The main goal is to see if the drug is safe and whether it can impro…
Phase 2 • Sponsor: Cumberland Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
MS treatment showdown: does starting strong early prevent disability?
Disease control OngoingThis trial compares two treatment strategies for people with relapsing-remitting multiple sclerosis: starting with high-efficacy drugs early versus starting with standard first-line therapies and switching if needed. The study involves 900 participants across multiple sites and t…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New insulin pump system put to the test in 400-Person safety trial
Disease control OngoingThis study is checking if a new insulin pump (NMX8) and continuous glucose monitor (DS5/Simplera Sync) are safe for people with type 1 or type 2 diabetes. About 400 participants, ages 7 to 85, will first wear the sensor for up to 40 days, then use the pump for about 90 days while…
Sponsor: Medtronic MiniMed, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hip implant aims to cut repeat surgeries
Disease control OngoingThis study is testing a new hip implant called the OR3O Dual Mobility System in 177 people who need hip replacement surgery. The goal is to see if the implant is safe and lasts longer without needing another surgery. Researchers will follow participants for up to 10 years to chec…
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy could tame tough lupus
Disease control OngoingThis study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
One-Time cell therapy aims to tame tough scleroderma
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with severe scleroderma that hasn't improved with standard care. About 96 participants will receive either this one-time cell therapy or the current drug rituximab.…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can early MS patients pause treatment? new trial seeks answers
Disease control OngoingThis study looks at whether people with early relapsing multiple sclerosis (MS) can stop taking ocrelizumab (Ocrevus) after two years without their disease coming back. All 123 participants will receive ocrelizumab for the first two years. Then, some will switch to a placebo whil…
Phase 4 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could a One-Time cell therapy ease myasthenia gravis? new trial launches
Disease control OngoingThis phase 3 study tests an experimental treatment called Descartes-08 for adults with generalized myasthenia gravis, a condition causing muscle weakness. The therapy uses modified immune cells (mRNA CAR T-cells) to target the disease. About 100 participants will receive either t…
Phase 3 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Weekly insulin shot could replace daily shots for type 1 diabetes
Disease control OngoingThis study compares a new insulin that is injected once a week (insulin icodec) to a standard daily insulin (insulin glargine) in about 877 adults with type 1 diabetes. The goal is to see if the weekly insulin controls blood sugar just as well as the daily one. Participants will …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot aims to restore skin color in vitiligo patients
Disease control OngoingThis early-stage trial tests a new drug called TEV-53408 in 38 adults with vitiligo. The main goal is to see if the drug is safe when given as a shot under the skin. Researchers will also look for early signs that it might help bring back skin color. The study lasts 84 weeks, inc…
Phase 1 • Sponsor: Teva Branded Pharmaceutical Products R&D LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New study tests belimumab to tame early lupus
Disease control OngoingThis study is testing the drug belimumab (Benlysta) in 350 adults who were diagnosed with systemic lupus erythematosus (SLE) within the last two years and still have active disease despite standard treatment. The goal is to see if adding belimumab helps more people reach a state …
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Double immune attack: can two drugs save Insulin-Making cells in new diabetes?
Disease control OngoingThis study tests whether giving two immune-calming drugs (rituximab followed by abatacept) can better preserve the body's ability to make insulin in people newly diagnosed with type 1 diabetes, compared to rituximab alone. About 74 participants aged 8 to 45 will receive the drug …
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug M281 aims to tame rare blood disorder
Disease control OngoingThis study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …
Phase 2/3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Which MS treatment strategy preserves the brain better?
Disease control OngoingThis trial asks whether starting with highly effective MS drugs right away is better than starting with milder drugs and switching to stronger ones only if needed. Researchers will follow about 800 adults with relapsing-remitting MS for several years, using MRI scans and disabili…
Phase 4 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New shot could help celiac patients who still suffer despite strict diet
Disease control OngoingThis study tests a drug called amlitelimab in adults with celiac disease who still have symptoms even after following a gluten-free diet for at least a year. About 229 participants will receive either the drug or a placebo as a shot under the skin for up to 28 weeks. The goal is …
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could MS patients switch to once-yearly infusions? new trial aims to find out
Disease control OngoingThis phase 3 trial tests whether people with active multiple sclerosis who have been stable on Ocrevus for at least two years can safely switch to annual infusions instead of the standard every-6-month schedule. The goal is to see if the less frequent dosing is just as good at pr…
Phase 3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New biologic shot aims to stop psoriatic arthritis joint damage
Disease control OngoingThis phase 3 trial tested guselkumab, a biologic drug given as a shot, in over 1,000 people with active psoriatic arthritis who had not responded well to other treatments. The goal was to see if it reduces symptoms like joint pain and swelling and slows joint damage seen on X-ray…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for spine pain in psoriatic arthritis: guselkumab under study
Disease control OngoingThis phase 4 trial tests whether guselkumab (TREMFYA) can reduce spine-related symptoms in people with active psoriatic arthritis who have not used biologic drugs before. About 411 participants will receive either guselkumab or a placebo as a shot under the skin. The main goal is…
Phase 4 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New shoulder implant tested for long-term relief in severe tears and arthritis
Disease control OngoingThis study follows 200 adults who receive the Shoulder iD™ implant to treat severe rotator cuff tears or shoulder arthritis. Researchers measure how well the shoulder works and how often the implant needs to be fixed or replaced over 10 years. Participants attend regular check-up…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill could ease joint pain for psoriatic arthritis patients
Disease control OngoingThis study tests an experimental drug called JNJ-77242113 (icotrokinra) against a placebo in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The main goal is to see if the drug reduces joint swelling and tenderness after 16 weeks. Partici…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Children with Crohn's, colitis, or psoriatic arthritis get long-term safety check on stelara
Disease control OngoingThis study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug nipocalimab tested in 655 Sjogren's patients in major trial
Disease control OngoingThis phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a nerve stimulator calm rheumatoid arthritis?
Disease control OngoingThis study tests whether an implantable vagus nerve stimulation device can safely reduce symptoms of rheumatoid arthritis in adults who have not gotten enough relief from at least two biologic or targeted synthetic DMARDs. Participants receive the device, which sends electrical p…
Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a pill keep vitiligo at bay? new study aims to find out
Disease control OngoingThis study tests a daily pill called ritlecitinib in adults and teens with nonsegmental vitiligo, a condition that causes white patches on the skin. The goal is to see if the medicine can maintain or improve skin color regained in a previous study, or if stopping it leads to colo…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a daily inhaled protein restore lung function in a rare autoimmune disease?
Disease control OngoingThis trial tests whether inhaling molgramostim—a lab-made version of a protein that helps lung cells clear out protein buildup—can improve lung function in adults with autoimmune pulmonary alveolar proteinosis (aPAP). In this condition, the immune system blocks a key signal, caus…
Phase 3 • Sponsor: Savara Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New ankle implant tracked for 10 years in arthritis patients
Disease control OngoingThis study follows 200 adults with ankle arthritis who received the INFINITY ankle replacement. Researchers will check how long the implant lasts and monitor for any problems like loosening or cysts over 10 years. The goal is to see if this device works as well as other similar i…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called ianalumab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 436 participants receive either ianalumab or a placebo as a shot under the skin, once a month or once every three months, along with their u…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Ublituximab shows promise for Long-Term MS control in large extension trial
Disease control OngoingThis study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track r…
Phase 3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
MS patients may soon get a shot instead of an IV drip
Disease control OngoingThis phase 3 trial tests whether a shot (subcutaneous) of ublituximab works as well as the standard IV infusion for people with relapsing multiple sclerosis. About 360 participants are enrolled. The main goal is to compare drug levels in the blood over 24 weeks, along with safety…
Phase 3 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments helps control active disease better than placebo. About 288 people aged 12 and older with systemic lupus erythematosus (SLE) are taking part. The main goal is to see if ianalumab…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New shot could tame lupus kidney flares
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic injection) to standard therapy helps control active lupus nephritis, a serious kidney complication of lupus. About 452 adults with active lupus nephritis are receiving either ianalumab every 4 or 12 weeks or a placebo,…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Could a personalized diet tame rheumatoid arthritis and protect the heart?
Disease control By invitation onlyThis study tests whether a personalized diet, based on the latest Nordic Nutrition Recommendations, can reduce disease activity and cardiovascular risk in people newly diagnosed with rheumatoid arthritis. About 150 participants will be randomly assigned to either a diet following…
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a simple pill save Insulin-Making cells in type 1 diabetes?
Disease control OngoingThis phase 2 trial tests whether the drug DFMO can protect the body's remaining insulin-producing cells in people recently diagnosed with type 1 diabetes. About 81 participants will take either DFMO or a placebo twice daily for six months. Researchers will measure insulin product…
Phase 2 • Sponsor: Emily K. Sims • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for chronic blood disorder: combo therapy aims to keep platelets stable
Disease control OngoingThis study tests whether adding ianalumab to standard eltrombopag treatment helps adults with immune thrombocytopenia (ITP) who did not get better with steroids. ITP causes low platelet counts, raising bleeding risk. The trial involves 152 participants and measures how long the t…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Smart pen could make insulin dosing easier for teens with diabetes
Disease control OngoingThis study tests whether a Bluetooth-enabled smart insulin pen, called InPen, can help teenagers with type 1 diabetes better control their blood sugar. The device helps calculate insulin doses and tracks injections, which may reduce errors. The trial involves 34 teens aged 13-21 …
Sponsor: Wayne State University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New injection could help kids with lupus avoid flares
Disease control OngoingThis study tests a weekly injection of belimumab, a drug that blocks a protein involved in lupus inflammation, in 25 children aged 5 to 17 with active lupus. The goal is to see if the drug reaches similar levels in the blood as in adults and to check its safety. If it works, it c…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New pill shows promise in quieting MS brain lesions
Disease control OngoingThis Phase 2 trial tests fenebrutinib, an oral drug, in 109 people with relapsing multiple sclerosis. Participants receive either the drug or a placebo for 12 weeks, and researchers measure new brain lesions on MRI scans. The goal is to see if fenebrutinib can reduce disease acti…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Sjögren's drug ianalumab tested for Long-Term safety in 600-Patient trial
Disease control OngoingThis phase 3 study tests the long-term safety of ianalumab in 612 people with Sjögren's syndrome who already completed a year of treatment in earlier trials. Participants receive ianalumab or placebo injections for up to several more years. The goal is to see if the drug remains …
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a B-Cell blocker tame lupus?
Disease control OngoingThis phase 2 trial is testing whether an experimental drug called obexelimab can safely reduce disease activity in people with systemic lupus erythematosus (SLE). The study enrolls about 190 adults aged 18 to 70 with active lupus. Participants are randomly assigned to receive eit…
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a healthy diet prolong the 'Honeymoon Phase' in kids with type 1 diabetes?
Disease control OngoingThis pilot study is testing whether giving children (ages 6-17) newly diagnosed with stage 3 type 1 diabetes free weekly healthy foods and intensive nutrition counseling can help preserve their remaining insulin production. The study will enroll 20 children and measure how feasib…
Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New MS drug tolebrutinib tested for Long-Term safety in 2,500 patients
Disease control OngoingThis study tests the long-term safety of the drug tolebrutinib in 2,500 adults with relapsing or progressive multiple sclerosis. Participants previously took part in earlier trials and will continue taking tolebrutinib or a placebo for up to several years. The goal is to see if t…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Cheaper MS drug could match pricey standard in major trial
Disease control OngoingThis phase 3 trial tests whether rituximab, a cheaper drug, works as well as ocrelizumab for active multiple sclerosis. About 600 adults with relapsing or progressive MS will receive one of the two drugs. The main goal is to see if rituximab can prevent new brain lesions as effec…
Phase 3 • Sponsor: Rigshospitalet, Denmark • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New knee implant under review: could it ease arthritis pain?
Disease control OngoingThis study is testing the Persona Ti-Nidium knee implant in 240 people who need total knee replacement due to conditions like osteoarthritis or rheumatoid arthritis. The goal is to see if the implant is safe and improves knee function and pain. Participants will be followed over …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for kids with rare muscle disease: rozanolixizumab safety trial expands
Disease control By invitation onlyThis study looks at the long-term safety of a drug called rozanolixizumab in children aged 2 and older with generalized myasthenia gravis, a condition that causes muscle weakness. The drug is given in 6-week treatment cycles. The main goal is to track serious side effects and see…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New MS pill aims to slow disability in phase 3 showdown
Disease control OngoingThis study compares two daily pills—fenebrutinib and teriflunomide—in about 746 adults with relapsing multiple sclerosis. The goal is to see which one better reduces relapses and delays worsening disability. Participants take one of the two drugs for several years, with an option…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
MS drug ocrelizumab gets a Needle-Free makeover: new shot form tested
Disease control OngoingThis early-stage trial is testing a new way to give ocrelizumab (Ocrevus) for multiple sclerosis — as a simple shot under the skin instead of a long IV infusion. About 75 adults with MS will receive increasing doses to see if the new form is safe and tolerable. If it works, it co…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug sonelokimab aims to ease psoriatic arthritis pain
Disease control OngoingThis study tests a drug called sonelokimab in 960 adults with active psoriatic arthritis who have not used biologic treatments before. The goal is to see if it reduces joint pain and swelling better than a placebo. Participants receive injections over several months, and research…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug could free diabetics from insulin after cell transplant
Disease control OngoingThis study tests whether a lab-made antibody called Tegoprubart can safely prevent the immune system from attacking transplanted islet cells in people with type 1 diabetes who have dangerous low blood sugar. The goal is to help patients stop needing insulin without using standard…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Hope for rare Muscle-Weakening disease: new drug trial targets Antibody-Negative patients
Disease control OngoingThis study tests an investigational drug called efgartigimod, given intravenously, for adults with generalized myasthenia gravis (gMG) who do not have the typical acetylcholine receptor antibodies. The trial compares the drug to a placebo to see if it improves daily activities an…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could a simpler dosing schedule for an MS drug work just as well?
Disease control OngoingThis study tests a new maintenance dosing schedule for ofatumumab, a drug used to control relapsing multiple sclerosis (MS). Researchers want to see if the new schedule is as safe and effective as the current approved dose. About 196 adults with relapsing MS will take part, and t…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for tough nerve disease: experimental drug riliprubart enters final testing
Disease control OngoingThis study tests a drug called riliprubart in 140 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hasn't improved with standard care. Participants receive either riliprubart or a placebo for up to 111 weeks. The main goal is to see if the drug reduces di…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New lupus drug candidate enters Mid-Stage trial
Disease control OngoingThis Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New ocrelizumab formula under study for MS patients
Disease control OngoingThis study compares two versions of the drug ocrelizumab given as a shot under the skin in people with multiple sclerosis. The goal is to see if the new test version works the same as the current one. About 182 participants with relapsing or primary progressive MS will take part.
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for lupus skin sufferers: Long-Term drug trial launches
Disease control By invitation onlyThis study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New study puts omnipod 5 to the test in Real-World diabetes management
Disease control OngoingThis study is testing the Omnipod 5, a tubeless insulin pump that automatically adjusts insulin delivery, in real-world settings for people with type 1 diabetes. About 304 participants aged 2 and older will use the system for the first time. Researchers will track blood sugar con…
Sponsor: Insulet Corporation • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Engineered immune cells take on lupus in first human test
Disease control OngoingThis early-phase trial is testing a one-time treatment called obecabtagene autoleucel (obe-cel) for people with severe lupus that hasn't improved with standard treatments. Obe-cel is made by taking a patient's own immune cells, engineering them to target and attack faulty B cells…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could this IV drug tame lupus kidney flares?
Disease control OngoingThis phase 3 study tests anifrolumab, an IV drug, against placebo in 359 adults with active lupus nephritis (kidney inflammation from lupus). The main goal is to see if more patients achieve complete kidney response, meaning better kidney function and less protein in urine. The t…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New hope for kids with rare muscle disease: Long-Term drug safety trial begins
Disease control By invitation onlyThis study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains …
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could a stronger dose of an MS drug keep disability at bay?
Disease control OngoingThis study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
MS drug ocrelizumab tested for Long-Term safety in 1,300 patients
Disease control OngoingThis study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over many years. Participants continue their usual treatment, and researchers track side effects, disability changes, and brain scans. The goal is …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New shot may tame stubborn lupus skin lesions
Disease control OngoingThis study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New pill aims to slash severe hypoglycemia in type 1 diabetes
Disease control OngoingThis study tests an experimental pill called cadisegliatin taken alongside insulin in adults with type 1 diabetes. The goal is to see if it can lower the number of dangerously low blood sugar events (hypoglycemia) without worsening overall blood sugar control. About 150 participa…
Phase 3 • Sponsor: vTv Therapeutics • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug aims to tame Graves' disease Long-Term
Disease control By invitation onlyThis study tests a drug called IMVT-1402 in adults with Graves' disease, a condition where the immune system attacks the thyroid. The goal is to see if the drug can help patients stay healthy without needing other treatments. About 372 people who completed earlier studies will ta…
Phase 2 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
Disease control OngoingThis Phase 2 study tests a drug called DNTH103 (claseprubart) in 65 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either the drug or a placebo, first through an IV and then as injections under the skin every two weeks for…
Phase 2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New lupus shot shows promise in major trial
Disease control OngoingThis study tests a new medicine called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe lupus. The goal is to see if it can better control disease activity compared to a placebo, when added to standard treatments. About 367 participants are involved…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Could a stronger dose of ocrevus slow MS disability better?
Disease control OngoingThis Phase 3 trial is testing whether a higher dose of the drug ocrelizumab (Ocrevus) can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS are receiving either the standard approved dose or a higher dose b…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a JAK-Inhibitor cream recolor white patches caused by cancer treatment?
Disease control OngoingThis study tests whether a topical cream containing ruxolitinib can safely restore skin color in people who develop white patches (vitiligo-like depigmentation) as a side effect of cancer immunotherapy. The cream is applied twice daily for 52 weeks. Researchers will measure how m…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for progressive MS: ocrelizumab trial targets disability
Disease control OngoingThis study is testing the drug ocrelizumab in 927 people with progressive multiple sclerosis (MS), a form of the disease that steadily worsens. Participants receive infusions every 24 weeks for about 4 years. The main goal is to see if the drug can stop or slow disability progres…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Digital dashboard aims to transform diabetes care for kids
Disease control By invitation onlyThis study tests whether a digital platform called Haibu Diabetes helps children with type 1 diabetes manage their condition better. The platform collects health data from devices and shares it with patients, caregivers, and doctors through a single dashboard. Researchers will co…
Sponsor: University of British Columbia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New lupus pill shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…
Phase 2 • Sponsor: Alumis Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New lupus drug enpatoran tested for long-term safety
Disease control OngoingThis study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…
Phase 2 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New MS drug frexalimab faces off against standard treatment in major trial
Disease control OngoingThis phase 3 trial compares the experimental drug frexalimab to the approved drug teriflunomide in about 1,655 adults with relapsing multiple sclerosis. The main goal is to see if frexalimab reduces the number of relapses more effectively. Participants receive either frexalimab i…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug RAY121 tested for Long-Term control of autoimmune diseases
Disease control By invitation onlyThis study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …
Phase 1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Psoriasis drug bimekizumab: new study looks at gene changes
Disease control OngoingThis study tests the drug bimekizumab in 89 adults with moderate to severe plaque psoriasis, some of whom also have psoriatic arthritis. Researchers will measure changes in gene activity in skin samples after 48 weeks of treatment. The goal is to understand how the drug affects t…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for kids with MS: major drug showdown begins
Disease control OngoingThis study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New MS drug copycat aims to match ocrevus in early trial
Disease control OngoingThis Phase 1 trial compares a new drug called RPH-035 to the approved MS drug Ocrevus. The study involves 180 adults with relapsing-remitting or secondary progressive multiple sclerosis who have flare-ups. Researchers are checking if RPH-035 behaves similarly in the body and has …
Phase 1 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Old gout drug could help hearts of people with type 1 diabetes
Disease control OngoingThis phase 2 trial tests whether a daily low dose of colchicine, an anti-inflammatory drug used for gout, can reduce inflammation and heart disease risk in adults with type 1 diabetes. 102 participants aged 35–80 will take either colchicine or a placebo for 26 weeks, with an opti…
Phase 2 • Sponsor: Asger Lund, MD • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a 4-Minute chat rival a Dietitian's hour for heart health?
Disease control OngoingThis study tests whether a short, standardized 4-minute heart-healthy talk is as effective as a full 60-minute personalized session with a dietitian for lowering LDL cholesterol and improving diet. Participants are adults aged 30–80 with rheumatoid arthritis, psoriatic arthritis,…
Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug duo aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThis study tests two experimental drugs, pozelimab and cemdisiran, alone or together, in 288 adults with generalized myasthenia gravis (gMG), a disease that causes muscle weakness and fatigue. The goal is to see if the drugs improve daily activities and muscle strength. Participa…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a Once-Daily steroid pill improve blood sugar control in Dual-Disease patients?
Disease control CancelledThis trial tests whether taking hydrocortisone once a day (as a dual-release pill) leads to more stable blood sugar levels compared to the standard three-times-a-day regimen in adults who have both insulin-treated diabetes and Addison's disease. Participants will try both schedul…
Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Withdrawn study sought to boost RA remission with education and team care
Disease control CancelledThis study was designed to test whether a combination of an educational booklet, team-based care from a rheumatologist, physical therapist, and psychologist, plus nurse-led phone calls and home symptom tracking, could help more Hispanic adults with rheumatoid arthritis achieve re…
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New shot could ease droopy eyelids in rare muscle disease
Disease control OngoingThis study tests a drug called efgartigimod for adults with ocular myasthenia gravis, a condition that causes eye muscle weakness like droopy eyelids or double vision. About 141 people will receive either the drug or a placebo for 7 weeks, then everyone gets the drug for up to 2 …
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Smart dosing strategy could keep rheumatoid arthritis under control
Disease control OngoingThis study compares two ways of managing rheumatoid arthritis in people taking adalimumab. One group gets standard care, while the other has their dose adjusted based on regular blood tests that measure drug levels and antibodies. The goal is to see if personalized dosing helps m…
Phase 4 • Sponsor: Diakonhjemmet Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a diabetes drug shield kidneys from lupus damage?
Disease control OngoingThis phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…
Phase 1/2 • Sponsor: Hospital Civil Juan I. Menchaca • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug aims to help type 1 diabetes patients keep making insulin
Disease control OngoingThis phase 2b trial tests frexalimab, an antibody that calms the immune system, in 192 adults and teens newly diagnosed with type 1 diabetes. The goal is to see if it can preserve the body's ability to produce insulin, reducing reliance on injections. Participants receive frexali…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New program helps older diabetics and caregivers share glucose data to improve health
Disease control OngoingThis study tests a program called Share plus for adults aged 60+ with type 1 diabetes and their care partners. The program helps them better use continuous glucose monitor data together. Researchers want to see if it improves blood sugar control and reduces diabetes-related stres…
Sponsor: University of Utah • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis Phase 3 study tests ritlecitinib, an oral drug, in adults with nonsegmental vitiligo, a condition causing white patches on the skin. About 1,571 participants will receive either 50 mg, 100 mg of ritlecitinib, or a placebo daily for up to 104 weeks. The goal is to see if the …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to tame Sjogren's syndrome in major trial
Disease control OngoingThis phase 3 study tests whether ianalumab, a biologic drug, can reduce disease activity and symptoms in people with active Sjogren's syndrome. About 506 adults with a recent diagnosis (within 7.5 years) and positive anti-Ro/SSA antibodies are randomly assigned to receive ianalum…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New study tests if ocrevus improves walking in MS patients
Disease control OngoingThis study looks at whether a one-year treatment with Ocrevus can improve walking and balance in people with relapsing multiple sclerosis, compared to other standard treatments. Sixty adults aged 18-65 who can walk at least 25 feet will be split into two groups. Their walking abi…
Phase 4 • Sponsor: Georgia State University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to tame type 1 diabetes
Disease control OngoingThis study is testing whether a combination of two drugs, sotagliflozin and volagidemab, can improve blood sugar control in adults with type 1 diabetes. The 24 participants will receive both drugs or a placebo in a crossover design. The goal is to see if this approach can help ma…
Phase 1/2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New biologic aims to stabilize platelet counts in ITP patients
Disease control OngoingThis phase 3 trial tests whether adding ianalumab (a biologic drug) to standard corticosteroids helps adults with newly diagnosed immune thrombocytopenia (ITP) achieve a stable platelet response off all treatments at 12 months. About 226 participants will receive either ianalumab…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
MS treatment gets personal: could tailored infusions be just as effective?
Disease control OngoingThis study compares the standard fixed-interval dosing of ocrelizumab (every 24 weeks) with a personalized approach where infusions are given only when B cell levels rise above a certain threshold. The goal is to see if the personalized schedule is just as good at preventing rela…
Phase 4 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThis Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for rare blistering disease: rituximab vs standard therapy
Disease control OngoingThis study compares two drugs, rituximab and cyclophosphamide, in 92 adults with severe mucous membrane pemphigoid, a rare autoimmune disease that causes painful blisters and scarring on mucous membranes. The goal is to see which treatment is safer and more effective at controlli…
Phase 3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Can schools help manage diabetes? new pilot study aims to find out
Disease control By invitation onlyThis study tests a new program where schools, families, and doctors work together to help children manage type 1 diabetes. About 30 kids will take part to see if the program is practical and well-liked. The goal is to improve daily diabetes care at school.
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a daily pill help restore skin color in vitiligo?
Disease control OngoingThis Phase 3 trial tests upadacitinib (Rinvoq), an oral immune-calming drug, in about 540 adults and teens with non-segmental vitiligo. Participants take a pill once daily for up to 160 weeks, with some receiving placebo first. The study measures how much skin color returns and t…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug SPY002-072 aims to tame multiple inflammatory joint diseases
Disease control OngoingThis Phase 2 study tests an experimental drug called SPY002-072 in 285 adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis. Participants receive either the drug or a placebo, and researchers measure changes in disease ac…
Phase 2 • Sponsor: Spyre Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill could help patients with rare blood disorder
Disease control OngoingThis study tests an experimental drug called rilzabrutinib in 22 adults with warm autoimmune hemolytic anemia (wAIHA), a condition where the immune system attacks red blood cells. Participants take the drug daily for up to 24 weeks, with an option to continue longer. The main goa…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
MS patients on ozanimod: how long does treatment last?
Disease control OngoingThis study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting ozanimod (Zeposia®) for the first time. Researchers want to see how long patients continue the medication in everyday practice and how well it controls their disease. The study…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple blood test guide MS treatment? new study tests ofatumumab switch
Disease control OngoingThis study looks at whether people with relapsing-remitting MS who have not had a relapse in the past year but have high levels of a nerve damage marker (NfL) in their blood would benefit from switching to the drug ofatumumab. About 136 participants will either switch to ofatumum…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Stem cell trial for rare bleeding disorder pulled before it began
Disease control CancelledThis study planned to test whether infusions of mesenchymal stem cells could safely help people with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial was withdrawn before enrolling any participants, so n…
Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Smart insulin pumps put to the test in thousands of diabetes patients
Disease control OngoingThis study follows 1,600 people with type 1 diabetes, including young children aged 2-6, who use hybrid closed-loop insulin pumps (Medtronic, Tandem, or Omnipod). These devices automatically adjust insulin based on blood sugar readings but still require users to enter meal inform…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
MS drug ofatumumab tested for Long-Term safety in nearly 1,900 patients
Disease control OngoingThis study follows about 1,900 people with relapsing multiple sclerosis who have already taken ofatumumab in a previous Novartis trial. Participants continue receiving ofatumumab injections every 4 weeks to monitor long-term safety, side effects, and how well the drug controls re…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Real-World study tests upadacitinib for back pain in axial spondyloarthritis
Disease control OngoingThis study looks at how well upadacitinib (RINVOQ) works for people with axial spondyloarthritis, a type of inflammatory arthritis that causes chronic back pain. About 338 adults in Germany will take the drug as prescribed by their doctor and be followed for 52 weeks. Researchers…
Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New RA pill takes on tofacitinib in Head-to-Head trial
Disease control OngoingThis phase 3 trial tests whether a new oral drug called TLL-018 works better than tofacitinib for active rheumatoid arthritis. The study includes 459 adults aged 18-65 who have not responded well to or cannot tolerate biologic treatments. Participants take either TLL-018 or tofac…
Phase 3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New implant aims to strengthen shoulder tendon repair after replacement
Disease control OngoingThis study is testing a special implant (Tapestry) that helps repair a key shoulder tendon (subscapularis) during shoulder replacement surgery. About 100 adults with shoulder arthritis or injury will be followed for 2 years to see if the tendon heals better with the implant. The …
Sponsor: Zimmer Biomet • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can magnetic waves tame autoimmune disease? new trial begins
Disease control By invitation onlyThis study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…
Phase 1/2 • Sponsor: Truway Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could Immune-Boosting drugs treat certain psychosis?
Disease control OngoingThis phase 2 trial tests whether a combination of intravenous immunoglobulin (IVIG) and rituximab can help people with psychosis caused by antibodies attacking the brain. 70 participants with acute psychosis and specific antibodies receive either the immunotherapy or a placebo. T…
Phase 2 • Sponsor: University of Cambridge • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising pill may halt vitiligo and bring back pigment
Disease control OngoingThis phase 2 trial tests deucravacitinib, a daily pill that targets the immune system, to see if it can stop vitiligo from spreading and help skin regain its color. About 128 adults with non-segmental vitiligo will take the drug or a placebo for 24 weeks, then some will also rece…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThis phase 2 trial tests whether tulisokibart can safely slow lung scarring in people with systemic sclerosis and interstitial lung disease. About 154 participants will receive either the drug or a placebo. The main goal is to see if the drug reduces the yearly decline in lung fu…
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for warm AIHA: drug trial targets blood cell destruction
Disease control OngoingThis study tests a drug called HMPL-523 (Sovleplenib) in people with warm antibody autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. About 111 adults will receive either the drug or a placebo to see if it improves hemoglobin levels and cont…
Phase 2/3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with MS: drug showdown begins
Disease control OngoingThis study tests two newer multiple sclerosis drugs, ofatumumab and siponimod, against an older one, fingolimod, in 129 children aged 10 to 17. The goal is to see if the newer drugs are at least as good at preventing MS relapses. Participants take one of the three drugs for two y…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Lupus drug trial hopes to tame flares with targeted antibody
Disease control OngoingThis Phase 3 study tests whether obinutuzumab, an antibody drug given by IV, can better control active lupus compared to a placebo. About 303 adults with lupus who have high disease activity and specific antibodies are taking part. All participants continue their usual lupus medi…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for progressive MS: drug aims to halt worsening disability
Disease control OngoingThis study tests an experimental drug called frexalimab in people with a type of progressive multiple sclerosis (MS) that is no longer causing relapses. The goal is to see if the drug can delay worsening disability compared to a placebo. About 943 adults aged 18 to 60 are taking …
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug aims to ease daily struggles of myasthenia gravis patients
Disease control OngoingThis study tests a drug called inebilizumab in 238 adults with myasthenia gravis, a condition that causes muscle weakness. The main goal is to see if the drug improves patients' ability to do daily activities over 26 weeks compared to a placebo. Participants must have specific an…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a weekly shot help type 1 diabetes patients lose weight and control blood sugar?
Disease control OngoingThis phase 3 trial tests tirzepatide, a once-weekly injection, in 905 adults with type 1 diabetes who are also overweight or obese. Participants will receive either tirzepatide or a placebo for about 49 weeks. The study measures changes in blood sugar control (HbA1c) and body wei…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a cancer drug slow MS progression? new trial halted midway
Disease control PausedThis phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib dela…
Phase 3 • Sponsor: AB Science • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo treatment for vitiligo shows promise in early trial
Disease control OngoingThis study tests whether injecting carbon dioxide gas (carboxytherapy) alongside standard narrowband UVB light therapy can improve repigmentation in people with stable vitiligo. Fifty-nine participants with symmetrical patches will receive whole-body UVB light, with carboxytherap…
Phase 4 • Sponsor: Kasr El Aini Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a psoriasis drug help save Insulin-Making cells in type 1 diabetes?
Disease control OngoingThis phase 2 trial tests whether ixekizumab (Taltz), a drug already approved for psoriasis, can help people newly diagnosed with type 1 diabetes keep making their own insulin. The study involves 127 adults aged 18-45 who were diagnosed within the last 100 days. Participants recei…
Phase 2 • Sponsor: Göteborg University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a pill tame lupus? large trial tests upadacitinib
Disease control OngoingThis phase 3 study tests whether upadacitinib (RINVOQ), a drug already used for arthritis, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. Researchers will measure how well it reduces disease acti…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Could a common supplement ease lupus?
Disease control OngoingThis study tests whether N-acetylcysteine (NAC), an antioxidant supplement, can help people with systemic lupus erythematosus (SLE). About 290 participants will first take NAC for 3 months to find a tolerable dose, then be randomly assigned to continue NAC or switch to a placebo …
Phase 2 • Sponsor: State University of New York - Upstate Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug tested for Long-Term safety in kids with rare muscle disease
Disease control By invitation onlyThis study looks at the long-term safety of efgartigimod in children with generalized myasthenia gravis, a disease that causes muscle weakness. The 12 participants are kids who already took part in earlier studies of this drug. They will continue to receive efgartigimod either th…
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingThis study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…
Phase 2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug hopes to tame hardening skin disease
Disease control PausedThis study tests a new drug called CM-101 for people with systemic sclerosis, a disease that causes skin hardening and organ damage. About 45 adults will receive either the drug or a placebo to check safety and how well the body tolerates it. The goal is to see if CM-101 can redu…
Phase 2 • Sponsor: ChemomAb Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Walking more could protect hearts of type 1 diabetes patients
Disease control OngoingThis study looks at whether doing light aerobic exercise five days a week can improve heart rate variability—a sign of heart health—in adults with type 1 diabetes. Over one year, 35 participants were split into two groups: one exercised regularly, the other less often. Researcher…
Sponsor: University of Banja Luka • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a tiny neck implant calm rheumatoid arthritis without pills?
Disease control OngoingThis study tests a small device implanted on the vagus nerve in the neck to treat moderate to severe rheumatoid arthritis. About 243 adults who did not get enough relief from standard drugs will receive either active or inactive stimulation for 12 weeks, then all will receive act…
Phase 3 • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New shot could tame Sjögren's symptoms in major trial
Disease control OngoingThis phase 3 trial tests whether efgartigimod, given as a shot under the skin, can reduce disease activity in adults with moderate-to-severe primary Sjögren's disease. About 631 participants will receive either the drug or a placebo for 48 weeks, with an option to continue treatm…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Dietary intervention aims to tame weight regain in Graves' patients
Disease control OngoingThis study tests whether a personalized low-calorie Mediterranean-style diet, combined with lifestyle coaching, can prevent people newly diagnosed with Graves' disease from regaining too much weight after their thyroid levels normalize. Fifty-four adults will be randomly assigned…
Sponsor: Istituti Clinici Scientifici Maugeri SpA • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
App aims to boost blood sugar control in type 1 diabetes
Disease control OngoingThis study tests whether a smartphone app called Hedia Diabetes Assistant can help adults with type 1 diabetes keep their blood sugar in a healthy range more often. About 154 people with poorly controlled diabetes will either use the app plus their usual care or just usual care f…
Sponsor: Hedia ApS • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Withdrawn study: could hydroxychloroquine help High-Risk pregnancies?
Disease control CancelledThis study was designed to see if adding hydroxychloroquine to standard treatment (aspirin and heparin) could help women with antiphospholipid syndrome have a healthy full-term pregnancy. It planned to enroll pregnant women before 14 weeks of gestation. However, the trial was wit…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Smart pump trial aims to tame tough diabetes cases
Disease control OngoingThis study tests whether a hybrid closed-loop insulin pump system (mylife CamAPS FX) can improve blood sugar control and quality of life in 30 adults with type 1 diabetes who have chronically high blood sugar and psychological challenges. Participants either start the pump immedi…
Sponsor: Jerzy Hohendorff • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New shoulder replacement system tracked in global study
Disease control By invitation onlyThis study is following 110 people who received a Tornier HRS shoulder replacement to see how well it improves pain and function. Participants have conditions like arthritis, fractures, or rotator cuff tears. The goal is to collect long-term safety and performance data for regula…
Sponsor: Stryker Trauma and Extremities • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
MS drug holiday for Over-50s: safe or risky?
Disease control OngoingThis study looks at whether people over 50 with a stable, inactive form of secondary progressive multiple sclerosis can stop taking their disease-modifying drugs without getting worse. Researchers will track 250 participants for 2 years to see if stopping treatment leads to more …
Phase 3 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill could tame Sjögren's syndrome
Disease control OngoingThis phase 3 trial tests deucravacitinib, an anti-inflammatory pill, in 774 adults with active Sjögren's syndrome. Participants receive either the drug or a placebo for 52 weeks. The goal is to see if the drug reduces disease activity and improves symptoms like dryness and fatigu…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Engineered immune cells take on lupus in tiny trial
Disease control OngoingThis Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…
Phase 2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Double-Drug attack on rheumatoid arthritis shows promise in new trial
Disease control OngoingThis Phase III trial tests whether combining baricitinib with an anti-TNF drug (adalimumab or etanercept) works better than baricitinib alone for people with rheumatoid arthritis who haven't responded to prior treatments. The study involves 160 adults aged 18-65 with active disea…
Phase 3 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Hard-to-Treat seizures: cenobamate under study
Disease control By invitation onlyThis study looks at whether the drug cenobamate can help reduce seizures in adults with autoimmune epilepsy, a condition where the immune system attacks the brain. Researchers will track 30 participants for 24 weeks to see if seizure frequency drops by at least half. The goal is …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a common supplement slow MS brain damage? new trial seeks answers.
Disease control OngoingThis study tests whether N-acetyl cysteine (NAC), a supplement, can protect the brain in people with progressive multiple sclerosis (MS). About 98 adults with primary or secondary progressive MS will receive either NAC or a placebo for 15 months. Researchers will measure brain sh…
Phase 2 • Sponsor: Emmanuelle Waubant, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
MS patients may benefit from switching Immune-Suppressing drugs
Disease control OngoingThis study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch imp…
Sponsor: Ente Ospedaliero Cantonale, Bellinzona • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug aims to save Insulin-Making cells in type 1 diabetes
Disease control OngoingThis study tests brivekimig, a drug that targets inflammation, to see if it can help people with newly diagnosed type 1 diabetes keep making their own insulin. About 84 adults and adolescents will receive either brivekimig or a placebo for 52 weeks. The main goal is to measure in…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can your own stem cells repair MS nerve damage? new trial aims to find out
Disease control OngoingThis early-phase trial tests whether a patient's own bone marrow stem cells, injected into the spinal fluid, can repair nerve damage caused by progressive multiple sclerosis. The study involves 18 adults with secondary or primary progressive MS. Researchers will measure changes i…
Phase 1/2 • Sponsor: Haukeland University Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for psoriatic arthritis: tildrakizumab shows promise in Long-Term trial
Disease control OngoingThis phase 3 study is testing the long-term safety and effectiveness of tildrakizumab, a biologic drug given as an injection, in people with psoriatic arthritis. Researchers are tracking side effects and how well the drug reduces joint pain, swelling, and other symptoms over time…
Phase 3 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug hope for rare blood disorder that causes anemia in cold weather
Disease control OngoingThis phase 2 trial tests the drug zanubrutinib (Brukinsa) in 25 people with primary cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures, causing anemia and poor circulation. The study aims to see if the drug can reduce an…
Phase 2 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
CAR-T cells take on rheumatoid arthritis in Head-to-Head trial
Disease control OngoingThis phase I/II trial compares a single dose of CAR-T cell therapy (KYV101) to two doses of rituximab in 13 people with active, treatment-resistant rheumatoid arthritis. The main goals are to check safety and see if the CAR-T treatment can turn off certain immune markers linked t…
Phase 1/2 • Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Vitamin e in knee implants: a Long-Term showdown
Disease control OngoingThis study looks at two kinds of plastic used in total knee replacement surgery: one with vitamin E and one without. The goal is to see which one lasts longer, causes less wear, and helps patients move better. About 605 adults with knee arthritis or similar problems took part, an…
Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New MS pill aims to slash relapses in major trial
Disease control OngoingThis phase 3 study tests an oral medication called IMU-838 against a placebo in about 1,100 adults with relapsing multiple sclerosis (MS). The goal is to see if the drug can reduce the number of relapses and new brain lesions over 72 weeks. Participants must be 18-55 years old wi…
Phase 3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New pill aims to stop MS relapses in its tracks
Disease control OngoingThis Phase 3 trial tests whether IMU-838 (vidofludimus calcium) can reduce relapses and brain lesions in adults with relapsing multiple sclerosis. Over 1,100 participants are randomly assigned to receive either the drug or a placebo for up to 72 weeks. The study is active but no …
Phase 3 • Sponsor: Immunic AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for progressive MS: ocrelizumab trial targets disability
Disease control OngoingThis phase 3 trial tests whether ocrelizumab (Ocrevus) can slow disability progression in adults with primary progressive multiple sclerosis (PPMS). Over 1,000 participants receive either the drug or a placebo. The main goal is to see if the drug delays worsening of hand function…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Hip replacement stem under review: 5-Year safety and performance study
Disease control OngoingThis study looks at the safety and performance of a cemented hip stem (TrendHip®) in 119 people who had hip replacement surgery. It tracks pain, function, and quality of life for up to 5 years after surgery. The goal is to confirm the device works well in everyday use.
Sponsor: Aesculap AG • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New biologic shot aims to tame painful skin disease
Disease control OngoingThis early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose level…
Phase 1 • Sponsor: Sonoma Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can Immune-Calming cells tame multiple sclerosis?
Disease control OngoingThis Phase 2 trial tests whether infusions of special immune cells (tolerogenic dendritic cells) can reduce brain lesions and relapses in people with relapsing-remitting multiple sclerosis. The 45 participants also take standard MS drugs. The study aims to see if this cell therap…
Phase 2 • Sponsor: Judit Pich • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could a weekly shot help type 1 diabetes patients shed pounds and control blood sugar?
Disease control OngoingThis phase 3 trial tests tirzepatide, a once-weekly injection, in 465 adults with type 1 diabetes who are also overweight or obese. Participants receive either tirzepatide or a placebo for about 20 months. The study measures changes in blood sugar control (HbA1c) and body weight …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Phase 1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis phase 3 study tests litifilimab, an experimental drug, in 548 adults with active systemic lupus erythematosus (SLE) who are already on standard treatments. Participants receive either high or low doses of litifilimab or a placebo as injections every 4 weeks for 52 weeks. The…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New knee implant under review: will it hold up?
Disease control OngoingThis study follows 100 people who received a new type of knee replacement device called EVOLUTION® NitrX™. The goal is to see how safe and effective it is over time. Participants have conditions like arthritis or knee damage. The main measure is a patient-reported score of knee f…
Sponsor: MicroPort Orthopedics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Email your doctor to beat gout: new trial tests remote care
Disease control OngoingThis study tests whether regular email communication between gout patients and their doctors can help lower uric acid levels more effectively than standard care. 204 adults with confirmed gout will either follow usual care or use a secure messaging system to adjust their medicati…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug aims to stop Flare-Ups in rare autoimmune disease
Disease control OngoingThis study tests a drug called obexelimab to see if it can prevent flare-ups in people with IgG4-related disease, a rare condition where the immune system attacks the body's own tissues. About 194 adults with active disease will receive either the drug or a placebo. The main goal…
Phase 3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a 14-Day drug delay diabetes in toddlers?
Disease control OngoingThis study tests a drug called teplizumab in 20 children under 8 who have early signs of type 1 diabetes (Stage 2). The goal is to check if the drug is safe and how the body handles it. Teplizumab works by calming the immune system to protect insulin-making cells. If successful, …
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Knee implant study tracks 10-Year performance
Disease control OngoingThis study looks at how well a specific knee replacement implant works over 10 years. Researchers are checking the safety and performance of the Legion knee implant in 126 people who already received it. The goal is to see how long the implant lasts and if it helps patients with …
Sponsor: Smith & Nephew, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for 52 weeks. The goa…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Can ocrelizumab tame MS inflammation from the start? new study aims to find out
Disease control OngoingThis study is testing whether the drug ocrelizumab (Ocrevus) can improve signs of inflammation in the spinal fluid of people newly diagnosed with relapsing multiple sclerosis (MS) or a high-risk first attack (clinically isolated syndrome). Thirty participants will receive ocreliz…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Common heart drug may shield eyes of type 1 diabetes patients
Disease control OngoingThis study tests whether fenofibrate, a drug typically used to lower blood fats, can slow the worsening of diabetic retinopathy (eye damage) in adults with type 1 diabetes. Over 400 participants take either fenofibrate or a placebo daily for three years. The goal is to see if the…
Phase 3 • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Drug access program offers hope for rare blood disorder patients
Disease control Expanded access (paused)This program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels…
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New CGM device aims to simplify diabetes management
Disease control By invitation onlyThis study is testing a new continuous glucose monitor (CGM) called the iCan o3 in 70 adults with type 1 or type 2 diabetes. Participants will wear the device for 60 days to see if it improves their blood sugar control, especially the time spent in a healthy range. The goal is to…
Sponsor: Sinocare • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Withdrawn before start: experimental cocktail for type 1 diabetes never tested
Disease control CancelledThis pilot study aimed to test whether a combination of four drugs—ATG, low-dose IL-2, adalimumab, and exenatide—could help people newly diagnosed with type 1 diabetes keep producing their own insulin. The trial planned to enroll adults aged 18-35 diagnosed within the last 120 da…
Phase 1/2 • Sponsor: Camillo Ricordi and Jay Skyler • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New shot shows promise for long-term platelet control in rare bleeding disorder
Disease control OngoingThis study tests a drug called efgartigimod given as a shot under the skin for adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The goal is to see if the drug is safe and helps maintain safe platele…
Phase 3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Phase 1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Pharmacists take on heart disease: new study tests community-based risk reduction
Disease control OngoingThis study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…
Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a blood filter help control type 1 diabetes?
Disease control OngoingThis early-phase study tests a treatment called extracorporeal photopheresis (ECP) for people with type 1 diabetes. ECP filters and treats a patient's blood with light and a drug, then returns it to the body. The goal is to see if this approach can reduce the need for insulin inj…
Early phase 1 • Sponsor: Abu Dhabi Stem Cells Center • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can cooking classes help kids with type 1 diabetes? new study tests a Kitchen-Based approach
Disease control OngoingThis study tests a 10-lesson family cooking and diabetes education program called DICE for 32 youth aged 8-14 with type 1 diabetes who struggle with blood sugar control. The program aims to improve blood sugar management and reduce health disparities by teaching families practica…
Sponsor: Case Western Reserve University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Teplizumab safety tracked for over 3 years in young diabetes patients
Disease control OngoingThis study follows 188 children and adolescents who completed the PROTECT study to check the long-term safety of teplizumab, an antibody treatment for recent-onset type 1 diabetes. Researchers will monitor side effects, insulin use, and blood sugar control for an additional 42 mo…
Sponsor: Provention Bio, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New lupus pill shows promise in major trial
Disease control OngoingThis study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill could tame lupus flares
Disease control OngoingThis Phase 3 trial tests whether the oral drug deucravacitinib can safely control moderate to severe lupus better than a placebo. About 516 adults with active lupus are taking either the drug or a dummy pill for several months. The goal is to see if the drug reduces lupus symptom…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a common diabetes drug protect arteries in type 1 diabetes?
Disease control OngoingThis study tests whether metformin, a drug used for type 2 diabetes, can slow the buildup of calcium in leg arteries of people with type 1 diabetes. 230 adults will take either metformin or a placebo for two years. The goal is to see if metformin reduces artery hardening, which c…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could stem cells ease MS symptoms? new trial tests hope
Disease control OngoingThis study tests a stem cell treatment (HB-adMSCs) for people with relapsing-remitting multiple sclerosis. The goal is to see if multiple infusions can improve quality of life and slow disability. Ten adults who previously received a placebo in an earlier trial will receive the t…
Phase 2 • Sponsor: Hope Biosciences Research Foundation • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could a gut procedure help control diabetes? new trial investigates
Disease control PausedThis study tests a procedure called duodenal mucosal resurfacing (DMR) using the Revita system in people with type 2 diabetes whose blood sugar is not well controlled with medication. About 320 adults will be randomly assigned to receive either the real procedure or a sham (fake)…
Sponsor: Fractyl Health Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Buddy up for better blood sugar: new study tests social support for young adults with diabetes
Disease control OngoingThis study tests a program called FAMS-T1D that helps young adults (ages 18-24) with type 1 diabetes set goals and get support from a friend or family member. The goal is to see if this approach improves blood sugar control, reduces diabetes distress, and helps the support person…
Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control CancelledThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could transplanted islets free diabetics from insulin?
Disease control OngoingThis study tests whether transplanting insulin-producing islet cells from donors into the liver can help people with type 1 diabetes control blood sugar without insulin shots. Ten participants receive strong anti-rejection drugs to protect the new cells. Researchers will track bl…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New oral drug shows promise for Long-Term control of rare bleeding disorder
Disease control OngoingThis study is for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. It tests the long-term safety and benefit of an oral drug called rilzabrutinib. Only 4 participants who already benefited fr…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New cell implant aims to curb severe low blood sugar in type 1 diabetes
Disease control CancelledThis study tested a new treatment called SR-02, which involves implanting insulin-producing cells into the abdomen of adults with type 1 diabetes who experience dangerously low blood sugar. Participants would need to take lifelong anti-rejection drugs to prevent the body from att…
Phase 1/2 • Sponsor: Seraxis • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can a drug save Insulin-Making cells in kids with New-Onset diabetes?
Disease control OngoingThis phase 2 trial is testing whether aldesleukin, a drug that helps regulate the immune system, can preserve insulin production in children and young adults (ages 6-18) recently diagnosed with type 1 diabetes. Participants receive either aldesleukin or a placebo for 6 months, an…
Phase 2 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Lupus drug sirolimus shows promise in phase 3 trial
Disease control OngoingThis phase 3 trial tests whether adding sirolimus (rapamycin) to standard treatment helps control active lupus better than placebo. 146 adults with active lupus despite standard care will receive either sirolimus or placebo for 24 weeks, with an option to continue for another 24 …
Phase 3 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Gene-Edited cell therapy for lupus trial pulled before it started
Disease control CancelledThis early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are availa…
Phase 1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
1304 RA patients tracked on filgotinib: will it hold up in real life?
Disease control OngoingThis study follows over 1300 adults with moderate to severe rheumatoid arthritis who are starting filgotinib (Jyseleca) as part of their normal care. Researchers will track how long patients stay on the drug, their pain, fatigue, and daily function over two years. The goal is to …
Sponsor: Alfasigma S.p.A. • Aim: Disease control
Last updated Jun 26, 2026 17:02 UTC
-
Could your own belly fat help fight MS?
Disease control PausedThis study tests whether a patient's own fat cells, processed into a special mixture called stromal vascular fraction, can safely improve quality of life and slow nerve damage in multiple sclerosis. About 100 adults with stable MS who have lasting nerve problems will receive an I…
Sponsor: Healeon Medical Inc • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
New hope for teens with MS: drug trial aims to cut relapses
Disease control OngoingThis study tests a drug called BIIB017 (Plegridy) in teenagers aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). It compares Plegridy to another MS drug, Avonex, to see which is safer and more effective at reducing relapses. The trial involves 152 participants and i…
Phase 3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
RA treatment showdown: low activity vs. remission
Disease control OngoingThis study compares two treatment strategies for rheumatoid arthritis (RA): aiming for low disease activity versus aiming for remission. 340 adults with RA who are starting or already on disease-modifying drugs will be randomly assigned to one of these targets. The goal is to see…
Sponsor: Sint Maartenskliniek • Aim: Disease control
Last updated Jun 26, 2026 15:30 UTC
-
Eye implant for diabetes? trial pulled before it began
Disease control CancelledThis study aimed to transplant insulin-producing cells into the front chamber of the eye for people with type 1 diabetes and poor vision. The goal was to see if the procedure was safe for the eye. However, the trial was withdrawn before enrolling any participants, so no results a…
Sponsor: Imperial College London • Aim: Disease control
Last updated Jun 26, 2026 13:07 UTC
-
Can PET scans reveal hidden brain inflammation in MS?
Diagnosis By invitation onlyResearchers at Mayo Clinic are testing whether advanced PET and MRI brain scans can measure inflammation in people with multiple sclerosis and other inflammatory demyelinating diseases. The study includes about 200 participants, both patients and healthy controls. Participants re…
Phase 2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a new PET tracer light up brain inflammation?
Diagnosis OngoingThis trial tests an experimental imaging tracer called [11C]-CS1P1, which is designed to attach to a protein involved in brain inflammation. The study will first check the tracer's safety and how it moves through the body in healthy volunteers, then compare its signals in people …
Sponsor: Tammie L. S. Benzinger, MD, PhD • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
Can a single platform predict your risk for multiple chronic diseases?
Diagnosis By invitation onlyThis pilot study is testing whether the ADEN platform can accurately identify people at risk for heart disease, respiratory problems, cancer, autoimmune conditions, and frailty. Researchers will compare the platform's risk ratings to those made by doctors. If it works, the platfo…
Sponsor: Unidad de Investigación Genética Molecular • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New blood test could spot type 1 diabetes before symptoms strike
Diagnosis OngoingThis study looks for tiny particles in the blood, called exosomes, that might signal the start of type 1 diabetes. Researchers will compare children recently diagnosed with type 1 diabetes to healthy children, all aged 12 to 18. The goal is to find a better way to catch the disea…
Sponsor: AdventHealth Translational Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Could a simple light scan replace the skin pinch test for scleroderma?
Diagnosis OngoingThis study is testing a new, non-invasive imaging technique called spatial frequency domain imaging (SFDI) to measure skin thickness in people with scleroderma, an autoimmune disease that causes skin hardening. Currently, doctors assess skin fibrosis by pinching the skin, which i…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
Blood test could unmask silent heart failure in diabetics
Diagnosis OngoingThis study tests whether a blood test for NT-proBNP can spot undiagnosed heart failure in 706 people with diabetes who are at high risk. Those with elevated levels get a heart ultrasound and exam. The goal is to see if this screening strategy leads to more early diagnoses and pro…
Sponsor: NHS Greater Glasgow and Clyde • Aim: Diagnosis
Last updated Jun 27, 2026 08:11 UTC
-
New MRI clue could slash MS misdiagnosis rates
Diagnosis OngoingThis study is testing whether a specific feature on brain MRI scans—called the central vein sign—can improve the accuracy of multiple sclerosis (MS) diagnosis. Currently, up to 1 in 5 people diagnosed with MS are later found not to have the disease, leading to unnecessary and pot…
Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
New test could make MS diagnosis faster and easier
Diagnosis By invitation onlyThis study looks at whether measuring kappa free light chains (KFLC) in spinal fluid can replace the standard test (oligoclonal bands) for diagnosing multiple sclerosis (MS) and its early stage, clinically isolated syndrome (CIS). Researchers will compare both tests in over 1,100…
Sponsor: Skripuletz, Thomas Prof. Dr. • Aim: Diagnosis
Last updated Jun 26, 2026 18:47 UTC
-
New test could predict falls in muscle disease patients
Diagnosis By invitation onlyThis study aims to create a simple test battery to determine fall risk in people with neuromuscular disorders, such as muscular dystrophy or ALS. Researchers will assess 108 participants using several physical tests like walking, standing, and rising from a chair. The goal is to …
Sponsor: LMU Klinikum • Aim: Diagnosis
Last updated Jun 26, 2026 16:30 UTC
-
Can a common antiplatelet drug replace warfarin after APS-Related stroke?
Prevention OngoingAntiphospholipid syndrome (APS) raises the risk of blood clots and strokes, and doctors often prescribe warfarin to prevent another stroke. Warfarin requires frequent blood tests and carries bleeding risks, especially for younger patients. This trial compares clopidogrel-based an…
Phase 4 • Sponsor: Seoul National University Hospital • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Early Gluten-Free diet or probiotics: a new strategy to prevent celiac disease?
Prevention OngoingResearchers are testing whether a gluten-free diet during the first three years of life, or daily probiotic supplements, can prevent celiac disease in children with a high genetic risk. The trial enrolls infants before they start eating gluten and randomly assigns them to one of …
Sponsor: Lund University • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Can we catch type 1 diabetes before it strikes?
Prevention By invitation onlyThis study tests whether screening children with a high genetic risk for type 1 diabetes, along with regular follow-up and family education, leads to an earlier diagnosis of the disease. Researchers will track 600 children to see if this approach prevents severe symptoms and diab…
Sponsor: Lund University • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
New program aims to cut heart risks in psoriasis patients
Prevention OngoingThis study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis reduce their risk of heart disease. About 520 adults aged 40-75 who do not already take cholesterol medication will receive support to manage risk factors like high cholest…
Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Low-gluten diet in toddlers may cut celiac risk, study finds
Prevention OngoingThis study looks at whether giving children with a genetic risk for celiac disease a low-gluten diet (less than 3 grams per day) during their first three years of life can lower their chance of developing the disease by age 7. About 1,100 children from Sweden are taking part. The…
Sponsor: Lund University • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
Could a cheap Fat-Lowering drug shield kidneys in type 1 diabetes?
Prevention OngoingThis pilot study tests whether fenofibrate, a generic drug used to lower blood fats, can prevent kidney function loss in people with type 1 diabetes who are at high risk of kidney failure. Forty participants will receive either fenofibrate or a placebo for 18 months, and their ki…
Phase 2 • Sponsor: Alessandro Doria • Aim: Prevention
Last updated Jun 27, 2026 09:02 UTC
-
Diet showdown: could paleo or keto diets ease MS symptoms?
Symptom relief OngoingThis study tests whether two special diets—a modified Paleolithic elimination diet and a time-restricted ketogenic diet—can improve quality of life, fatigue, and mood in 162 people with relapsing-remitting multiple sclerosis. Participants are assigned to one of the diets or stand…
Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Online course aims to boost diet and Self-Care for MS and fatigue patients
Symptom relief OngoingThis study is testing whether an online course can help people with multiple sclerosis, long COVID, fibromyalgia, or cancer-related fatigue adopt healthier diets and self-care habits. Researchers will measure changes in quality of life, fatigue, and mental health. The goal is to …
Sponsor: Terry L. Wahls • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a robotic exoskeleton rebuild arm strength after Guillain-Barré?
Symptom relief OngoingGuillain-Barré syndrome can leave people with weak arms and hands, making daily tasks hard. This trial tests whether adding robot-assisted arm training to usual therapy helps adults in the sub-acute phase of recovery. Participants use the Armeo Power 2 exoskeleton for 20 sessions…
Phase 4 • Sponsor: I.R.C.C.S. Fondazione Santa Lucia • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Could a new cycling style help MS patients walk better and feel less tired?
Symptom relief OngoingThis study tests a new type of cycling called eccentric cycling for people with multiple sclerosis. Researchers want to see if it improves muscle strength, walking ability, fatigue, and quality of life better than standard cycling. Sixty adults with MS who can walk independently …
Sponsor: University of Liege • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Could a wearable nerve stimulator help MS patients walk more freely?
Symptom relief By invitation onlyThis trial tests a wearable device that uses mild electrical pulses to stimulate the leg muscles of people with multiple sclerosis who have foot drop. The goal is to see if using the device for several months improves walking quality, physical activity, and participation in daily…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can a Job-Focused rehab program keep arthritis patients employed?
Symptom relief OngoingPeople with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis often struggle to stay in work. This trial tests a 6-month vocational rehabilitation program called WORK-ON, which includes a coordinating occupational therapist, group sessions with peers, and ind…
Sponsor: The Danish Center for Expertise in Rheumatology • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New app aims to bridge depression care gap for MS patients
Symptom relief OngoingThis study tests a smartphone app called MS CATCH that lets people with multiple sclerosis regularly report their mood to their neurologist. The goal is to improve how doctors screen and treat depression in MS. About 100 adults with MS and mild-to-moderate depression are taking p…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can treating the mind help control diabetes? new study tests integrated care
Symptom relief OngoingThis study tests whether adding mental health care to standard diabetes treatment improves mood and blood sugar control in adults with type 1 diabetes. Eighty participants will be randomly assigned to usual care or a collaborative care model that includes a behavioral health cons…
Sponsor: Emory University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Green tea compounds could soothe radiation burns in cancer care
Symptom relief By invitation onlyThis Phase 3 trial tests whether catechins (compounds found in green tea) given as a pill or spray can prevent or treat skin damage caused by radiation therapy. About 162 cancer patients will receive either catechins or a placebo, alongside standard care. The goal is to see if th…
Phase 3 • Sponsor: CARLOS FRANCISCO SAAVEDRA GARCIA • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
A personal nurse and a plan: could this ease the daily burden of arthritis?
Symptom relief OngoingThis trial tests a six-month program where a coordinating rheumatology nurse helps people with inflammatory arthritis set goals and plan actions to manage their condition. Participants also get access to physiotherapy, occupational therapy, and social work support as needed. The …
Sponsor: The Danish Center for Expertise in Rheumatology • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
2,000 MS patients sought for landmark fatigue study
Symptom relief By invitation onlyThis study tests two online programs designed to help people with multiple sclerosis (MS) understand and manage their fatigue. Researchers will enroll 2,000 adults with MS across the U.S., including veterans, and compare the programs to usual care alone. The goal is to find pract…
Sponsor: Accelerated Cure Project for Multiple Sclerosis • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Virtual Nurse-Led program aims to boost purpose in women with MS
Symptom relief OngoingThis study tests whether a six-week, nurse-led virtual group program can help adult women with Multiple Sclerosis (MS) find more meaning and purpose in life, and improve their quality of life. Participants attend weekly online group sessions focused on reflection and values explo…
Sponsor: Texas Woman's University • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Home telerehab may keep MS balance gains going after hospital therapy
Symptom relief OngoingThis pilot trial tests whether people with multiple sclerosis can safely and satisfactorily use a telemedicine platform for balance rehabilitation at home. After completing intensive in-hospital rehabilitation, participants either follow a 12-week home telerehabilitation program …
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Healing from home: virtual reiki tested for lupus pain relief
Symptom relief OngoingThis pilot study will test whether virtual Reiki therapy can reduce pain and improve well-being in people with lupus. Twenty adults with lupus will receive 20-minute Reiki sessions once a week for 8 weeks, delivered remotely by a certified practitioner. Researchers will measure c…
Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New app aims to keep MS patients on their feet
Symptom relief OngoingThis study tests a personal health app called MS FIT that lets people with multiple sclerosis log falls and near-falls, view their health data, and share it with their doctor. The goal is to improve communication about fall risks and provide educational tips. About 100 participan…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New program aims to help seniors master glucose monitors
Symptom relief OngoingThis study tests a remote education program called REST, designed to help adults aged 65 and older with insulin-treated diabetes start and keep using continuous glucose monitors (CGMs). The goal is to reduce dangerous low blood sugar episodes and improve overall glucose control. …
Sponsor: Joslin Diabetes Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Custom insoles may steady the steps of MS patients — a trial puts them to the test
Symptom relief OngoingThis trial tests whether custom-designed sensorimotor insoles, worn daily for six months, can improve balance and walking in people with multiple sclerosis. Fifty adults with MS (mild to moderate disability) will be randomly assigned to receive the insoles or continue their usual…
Sponsor: University of Salamanca • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Turmeric and blue light may heal blisters in rare skin disease
Symptom relief OngoingThis study tests whether a gel made from curcumin (the active part of turmeric) combined with blue LED light can heal painful mouth blisters in people with epidermolysis bullosa, a rare condition that makes skin and mucous membranes extremely fragile. Twenty participants will rec…
Phase 4 • Sponsor: Universidade Ceuma • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
New trial: could walking and thinking beat fatigue in muscle disease?
Symptom relief OngoingThis study tests whether 16 weeks of aerobic exercise or cognitive behavioral therapy can reduce severe fatigue in people with myasthenia gravis, a muscle weakness condition. Sixty adults with stable MG will be randomly assigned to exercise, therapy, or usual care. The goal is to…
Sponsor: Leiden University Medical Center • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New wearable device aims to tackle MS bladder issues from home
Symptom relief OngoingThis study tests whether a wearable device, used at home alongside pelvic floor therapy, can help people with multiple sclerosis manage bladder problems. Twenty women with MS will use the device for three months. The main goal is to see if the approach is practical and easy to us…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New study tests physical therapy to boost exercise in MS patients
Symptom relief OngoingThis study tests whether a 24-week physical therapy program can help people with multiple sclerosis become more physically active. Forty participants will receive tailored exercise support and education. The goal is to see if this approach is feasible and helps manage MS symptoms…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Spinal zaps at home could restore hand control in MS
Symptom relief By invitation onlyThis pilot study explores whether non-invasive electrical stimulation of the spinal cord, combined with hand and arm exercises, can improve upper limb function in people with multiple sclerosis. Participants use a home device with help from a partner over 8 weeks. The study focus…
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Peer support may help MS patients stay on track with meds
Symptom relief OngoingThis pilot study tests whether one-on-one peer support sessions can help people with relapsing-remitting multiple sclerosis stay on their prescribed medications. Sixty adults will be randomly assigned to receive either standard care or three hour-long sessions with a trained peer…
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Talking therapy aims to ease the emotional burden of type 1 diabetes
Symptom relief OngoingThis study tests whether cognitive behavioral therapy (a type of talking therapy) delivered online, along with a continuous glucose monitor, can reduce diabetes-related distress in adults with type 1 diabetes. About 93 adults aged 18-64 will be randomly assigned to receive either…
Sponsor: Albert Einstein College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Online workouts may boost brain speed in MS patients
Symptom relief OngoingThis study tests whether a guided internet-based physical activity program can improve cognitive processing speed in people with multiple sclerosis. 280 participants who have mild walking difficulties and slowed thinking will be randomly assigned to either the exercise program or…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Nerve-Zapping gadget could tame MS symptoms at home
Symptom relief OngoingThis study tests if a gentle, non-invasive nerve stimulation device can help manage symptoms of multiple sclerosis (MS), like fatigue and pain. Thirty women with MS will use the device at home for a few weeks. The goal is to see if it's practical and if it reduces symptom burden,…
Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Could a Low-Dose ketamine infusion beat MS fatigue?
Symptom relief OngoingThis phase 2 trial tests whether a single low-dose ketamine infusion can reduce fatigue in people with multiple sclerosis. About 110 adults with MS-related fatigue will receive either ketamine or a mild sedative (midazolam) as a placebo. The study measures changes in fatigue scor…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
New app aims to help type 1 diabetes patients exercise safely
Symptom relief By invitation onlyThis study tests a smartphone app called PACTAID in 20 adults with type 1 diabetes. The app gives real-time advice during exercise to help keep blood sugar levels stable while using an automated insulin pump. Researchers will check if the app improves glucose control during and a…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Brain zaps and VR games: a new hope for MS symptoms?
Symptom relief OngoingThis study tests whether combining transcranial magnetic stimulation (TMS) with virtual reality exercises and physical therapy can improve symptoms like balance, fatigue, and thinking in people with multiple sclerosis. Thirty participants will receive both real and sham TMS in a …
Sponsor: University of Sao Paulo • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can an online course keep arthritis patients working?
Symptom relief OngoingThis study tests an online program designed to help people with inflammatory arthritis remain employed. The program includes eLearning modules, group video sessions, and consultations with an occupational therapist and vocational counselor. About 528 participants from three Canad…
Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
ThyMoves study: exercise may ease thyroid symptoms and prevent falls in seniors
Symptom relief By invitation onlyThis study looks at whether a tailored exercise program can improve quality of life, muscle strength, and balance in women aged 65 and older with Hashimoto's thyroiditis or multinodular toxic goiter. Participants will be randomly assigned to either the exercise program or usual c…
Sponsor: Aalborg University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
New hope for MS brain fog: personalized therapy shows promise
Symptom relief OngoingThis study tests a cognitive rehabilitation program called CIRCuiTS, adapted for people with Multiple Sclerosis (MS). Twenty-four participants will either start the program right away or after a 13-week wait. The program involves up to 36 hours of therapist-led and independent se…
Sponsor: King's College London • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Lupus fatigue fight: coaching shows promise
Symptom relief OngoingThis study tests whether personalized coaching on physical activity and nutrition can reduce fatigue in people with lupus. 200 participants are split into two groups: one gets coaching on exercise and diet, the other gets general lupus education. The goal is to see if the coachin…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can a better diet ease MS symptoms? new study tests diet quality and calorie cutting
Symptom relief OngoingThis study looks at whether improving diet quality and reducing calories can help physical function, thinking, pain, fatigue, mood, and anxiety in 100 adults with relapsing-remitting or secondary progressive multiple sclerosis. Participants receive prepared meals and behavioral s…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Home-Based balance training shows promise for MS and Parkinson's patients
Symptom relief OngoingThis study tests whether a 4-week telerehabilitation program can improve balance and quality of life in 36 people with multiple sclerosis or Parkinson's disease. Participants do balance exercises at home while monitored by a hospital physiotherapist. The results are compared to s…
Sponsor: IRCCS San Camillo, Venezia, Italy • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Can a computer program help MS patients sleep better?
Symptom relief OngoingThis study tests whether a 9-week online cognitive behavioral therapy program can improve sleep in people with multiple sclerosis (MS). About 550 participants in Norway will either receive the digital therapy or digital education about insomnia. The main goal is to see if the the…
Sponsor: St. Olavs Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Healthy habits program aims to ease MS fatigue and boost Well-Being
Symptom relief OngoingThis study tests whether educational programs about exercise, Mediterranean diet, and mental strategies can improve quality of life and reduce fatigue in women with relapsing-remitting multiple sclerosis. About 60 participants will be assigned to either supervised in-person sessi…
Sponsor: Universidad de Almeria • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Metaverse therapy: could virtual cooking and escape rooms heal the brain?
Symptom relief OngoingThis study tests a set of virtual reality exergames in the Metaverse to help people with neurological conditions like multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury improve their cognitive skills. 25 participants will try games like virtual cooking an…
Sponsor: Istituto per la Ricerca e l'Innovazione Biomedica • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Poop pills could ease stomach troubles for scleroderma patients
Symptom relief OngoingThis study tests whether fecal microbiota transplantation (FMT) – giving healthy donor stool in capsules – can safely reduce chronic diarrhea in people with systemic sclerosis. Twenty adults with scleroderma and persistent diarrhea will receive either FMT or a placebo. The main g…
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Yoga coaching shows promise for lupus pain in small trial
Symptom relief OngoingThis study tests a personalized yoga coaching program for people with lupus who have chronic pain. Fifteen participants work with a coach to create a yoga practice that fits their needs and limits. The goal is to see if the program is feasible and if it helps reduce pain. It is a…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Exercise plus fish oil shows promise for MS fatigue and strength
Symptom relief By invitation onlyThis study will test whether taking a daily DHA (omega-3) supplement and doing therapeutic exercise three times a week can improve strength, fatigue, thinking, and quality of life in 100 people with multiple sclerosis. Participants will be randomly assigned to one of four groups:…
Sponsor: Francisco Javier Martínez Noguera • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Could a light bulb fight MS fatigue? small trial begins
Symptom relief By invitation onlyThis early-stage study tests whether a novel light therapy, designed to reset the body's internal clock, is safe and can reduce fatigue in people with progressive multiple sclerosis. Twenty participants will receive the light therapy while researchers monitor side effects and mea…
Phase 1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Exercise as medicine? new study tests High-Intensity workouts for rheumatoid arthritis
Symptom relief OngoingThis study looks at whether a 12-week program of high-intensity interval exercise can improve heart function, reduce inflammation, and boost quality of life in people with rheumatoid arthritis. 87 adults with stable, low-to-moderate disease activity will take part. The program in…
Sponsor: Vastra Gotaland Region • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Internet-Based coaching aims to boost activity in MS patients
Symptom relief OngoingThis study tests a 6-month online program designed to help people with multiple sclerosis become more physically active. Participants receive interactive video lessons, a step tracker, and one-on-one video chats with a coach. The goal is to see if the program increases daily acti…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New pain relief for diabetic nerves? trial pulled before start
Symptom relief CancelledThis study was designed to test a new drug called N0750 against two standard pain medications (Cymbalta and Lyrica) for painful diabetic peripheral neuropathy. It planned to enroll adults with diabetes and nerve pain for at least 3 months. However, the trial was withdrawn before …
Phase 3 • Sponsor: Eurofarma Laboratorios S.A. • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
RA injection study pulled before it even started
Symptom relief CancelledThis study aimed to test the safety of a new drug called F8IL10, given as a joint injection every 4 weeks for 8 weeks, in people with rheumatoid arthritis who still have joint flares despite standard treatments. The goal was to find the safest dose. However, the study was withdra…
Phase 1 • Sponsor: Philogen S.p.A. • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Can a home training program boost brain power in MS?
Symptom relief OngoingThis pilot study tests a home-based program called HOBSCOTCH, designed to help people with multiple sclerosis manage memory and thinking problems. Eleven participants will attend virtual coaching sessions and complete questionnaires about their quality of life and cognitive funct…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Antioxidant supplement NAC tested for MS brain health
Symptom relief By invitation onlyThis study tests whether N-acetyl cysteine (NAC), a common antioxidant supplement, can improve brain function and reduce inflammation in people with multiple sclerosis (MS). Researchers will use brain scans to measure changes in metabolism and inflammation. The study enrolls 55 a…
Sponsor: Thomas Jefferson University • Aim: Symptom relief
Last updated Jun 26, 2026 18:17 UTC
-
Home rehab for MS: safe and effective?
Symptom relief OngoingThis study tests whether a tele-rehabilitation program is safe and beneficial for people with multiple sclerosis (MS). 75 participants will do three online rehab sessions per week. Researchers will track side effects, quality of life, walking ability, mood, and fatigue, comparing…
Sponsor: Multiple Sclerosis Center of Catalonia • Aim: Symptom relief
Last updated Jun 26, 2026 17:46 UTC
-
Learning to live better: education program aims to ease rheumatoid arthritis struggles
Symptom relief OngoingThis study tests whether a 6-month patient education program can improve quality of life for people with rheumatoid arthritis. The program covers topics like understanding the disease, monitoring symptoms, treatment options, nutrition, and stress management. Researchers will comp…
Sponsor: Hassan II University • Aim: Symptom relief
Last updated Jun 26, 2026 15:58 UTC
-
Could a home brain stimulator ease arthritis pain?
Symptom relief By invitation onlyThis study tests whether a gentle electrical brain stimulation device, used at home, can reduce chronic pain in people with rheumatoid arthritis whose inflammation is already well-controlled. Thirty-four participants will either receive real or sham stimulation over several sessi…
Sponsor: Federal University of Rio Grande do Sul • Aim: Symptom relief
Last updated Jun 26, 2026 14:52 UTC
-
Major study tracks Real-World MG care in china
Knowledge-focused OngoingThis study follows about 1,200 people with myasthenia gravis (MG) across China to understand how the disease is treated in real-world clinics. Researchers will track symptoms, daily living abilities, quality of life, and healthcare use every 6 months until 2027. The goal is to le…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can Real-World data show how well multiple sclerosis patients stick with ofatumumab?
Knowledge-focused OngoingResearchers are studying how people with relapsing multiple sclerosis use ofatumumab in everyday practice in Germany and Japan. The study looks at insurance claims from about 5,000 adults to see how many stay on the treatment and how regularly they take it. It also tracks how oft…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
One bite of gluten: scientists track the immune alarm in celiac disease
Knowledge-focused By invitation onlyResearchers at Boston Children's Hospital are studying how the immune system reacts after a single oral dose of gluten powder. The study includes people with celiac disease and healthy controls, all of whom follow a gluten-free diet before the test. By measuring blood levels of i…
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can a handoff plan help teens with chronic illness take charge of their care?
Knowledge-focused OngoingResearchers are testing a transition program for 17-year-olds with type 1 diabetes, asthma, or obesity who are preparing to move from pediatric to adult healthcare. The program includes a consultation with the teen and family, a solo visit where the teen completes a readiness che…
Sponsor: Universiteit Antwerpen • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Lupus care under the microscope: new registry tracks Real-World treatment in kazakhstan
Knowledge-focused OngoingThis study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are b…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can amniotic cell secretions shield nerves in ALS and MS?
Knowledge-focused OngoingResearchers are collecting blood and skin samples from people with ALS, people with MS, and healthy volunteers. They turn skin cells into stem cells and grow them into 3D organoids that mimic the brain and spinal cord. The goal is to see whether secretions from human amniotic mes…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Hidden muscle loss in Sjögren's syndrome: a new study looks for answers
Knowledge-focused OngoingThis study examines whether women with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth, also experience muscle loss, a condition called sarcopenia. Researchers will measure muscle strength, muscle mass, and physical performance in 120 participants…
Sponsor: Antalya Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Massive medicare study aims to improve joint replacement safety
Knowledge-focused OngoingThis study looks at records from over 500,000 Medicare beneficiaries with rheumatoid arthritis or ankylosing spondylitis who had major orthopedic procedures like joint replacements or spine surgery between 1999 and 2015. Researchers want to understand how often complications happ…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Will a new drug form work the same? study tests two versions of SKI-O-703
Knowledge-focused OngoingThis study tests whether two different capsule forms of the experimental drug SKI-O-703 are absorbed similarly in the body. About 48 healthy adults (Korean and Caucasian) will take a single dose of each form on separate days, with blood samples taken to compare drug levels. The r…
Phase 1 • Sponsor: Oscotec Inc. • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Brain shrinkage as a crystal ball for MS progression?
Knowledge-focused By invitation onlyThis observational study follows about 2,400 people with relapsing-remitting multiple sclerosis (MS) across Germany for up to six years. It asks whether loss of volume in the thalamus—a deep brain region—tracks with worsening disability, measured by the EDSS scale. Using standard…
Sponsor: Jung Diagnostics GmbH • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Massive psoriasis registry tracks drug safety over years
Knowledge-focused OngoingThis study is a large registry that follows nearly 16,000 people with psoriasis to monitor the long-term safety of several treatments, including biologic drugs like infliximab and ustekinumab. Participants receive their usual care while researchers track side effects, disease act…
Sponsor: Janssen Scientific Affairs, LLC • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Psoriatic arthritis drug showdown: which treatment do patients stick with?
Knowledge-focused OngoingThis study follows over 1,300 people with psoriatic arthritis who are starting either guselkumab (Tremfya) or an IL-17 inhibitor as part of their routine care. Researchers will track how long patients continue each treatment and monitor joint swelling and tenderness. The goal is …
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
1,000 patients join hunt for stomach cancer early warning signs
Knowledge-focused By invitation onlyThis study follows 1,000 people with stomach pre-cancer conditions like chronic gastritis and intestinal metaplasia. Researchers will track disease progression over time and analyze biospecimens to find biomarkers linked to cancer development. The goal is to better understand who…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can Real-World data improve diabetes care in pregnancy?
Knowledge-focused OngoingThis study gathers real-world information from pregnant women with type 1 diabetes in the United States to understand how they manage their condition. Participants share data from their continuous glucose monitors and insulin pumps, and complete online surveys. The goal is to lea…
Sponsor: Jaeb Center for Health Research • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
New screening study targets hidden diabetes and celiac disease in High-Risk communities
Knowledge-focused OngoingThis study is screening 115 underserved children and adults who are at risk for type 1 diabetes or celiac disease. Researchers will use blood tests to find early signs of these conditions, aiming to improve how we detect them. The goal is to catch these diseases sooner, especiall…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
MS drug levels in breast milk under study for nursing moms
Knowledge-focused OngoingThis study looks at how much of the multiple sclerosis drug ofatumumab gets into breast milk. About 24 women with relapsing MS who are breastfeeding and starting or restarting ofatumumab will provide milk samples. The goal is to measure drug concentrations, which may help guide f…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New program aims to ease diabetes care transition for teens
Knowledge-focused OngoingThis study tests a program called SHIFT2 that helps teens and young adults with type 1 diabetes prepare for the switch from pediatric to adult medical care. Participants work with a transition coach and receive messages to encourage self-management. The goal is to see if this sup…
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Can a biologic drug tame juvenile arthritis in kids?
Knowledge-focused CancelledThis study follows children aged 6 to 17 with active juvenile enthesitis-related or psoriatic arthritis who are being treated with secukinumab. Researchers will track how long children stay on the drug, how much their symptoms improve, and whether they achieve remission. The goal…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
A 20-Minute walk: a new way to boost brain health in MS?
Knowledge-focused OngoingThis study explores whether a brief, moderate-intensity walk can alter brain function and blood flow in people with multiple sclerosis. Participants will undergo MRI scans before and after either treadmill or overground walking at a brisk pace. The goal is to see if even a single…
Early phase 1 • Sponsor: Kessler Foundation • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a smartphone app help teens with lupus and depression stay on track?
Knowledge-focused OngoingThis study aims to understand how depression symptoms, like loss of interest, may make it harder for teens and young adults with lupus to keep up with their medical care. Researchers will also test a mobile health app designed to provide education and connect users to their care …
Sponsor: Montefiore Medical Center • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New app and MRI tool aim to improve MS care
Knowledge-focused PausedThis study tests a digital platform that combines an app for patients and a brain-scan analysis tool for doctors. The goal is to see if it helps monitor multiple sclerosis (MS) more easily in everyday care. About 500 people with relapsing-remitting MS will use the app and have th…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Simple tests could revolutionize chronic pain diagnosis
Knowledge-focused OngoingThis study aims to improve how doctors diagnose and treat chronic muscle and joint pain by using simple questionnaires and pain sensitivity tests. Researchers will study 250 adults with conditions like osteoarthritis, fibromyalgia, chronic low back pain, or inflammatory arthritis…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
MS crystal ball: new biomarkers aim to predict disability before it strikes
Knowledge-focused OngoingThis study follows 300 people with multiple sclerosis to see whether advanced MRI scans, eye tests, and blood markers can better predict when disability will worsen. Current tools are not accurate enough to guide early treatment for each individual. The researchers will compare t…
Sponsor: EDMUS Foundation • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Massive MS registry aims to decode why some patients worsen faster than others
Knowledge-focused OngoingThis observational study follows thousands of people with multiple sclerosis (MS) over many years to identify factors that predict how the disease will progress. Researchers collect detailed clinical data, MRI scans, and quality-of-life questionnaires from participants treated at…
Sponsor: EDMUS Foundation • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
New brain scanner could reveal hidden effects of childhood neurological diseases
Knowledge-focused OngoingThis study uses a new, child-friendly brain imaging technique called OPM-MEG to understand how immune-related brain diseases (like autoimmune encephalitis and multiple sclerosis) and other brain conditions affect children aged 2 to 25. Standard scans often miss problems with memo…
Sponsor: Aston University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Digital diary aims to decode painful flares in spine condition
Knowledge-focused OngoingThis study investigates how people with axial spondyloarthritis (axSpA) experience sudden worsening of symptoms, known as flares. Over 12 months, 40 participants use a digital diary to track symptoms, diet, lifestyle, and self-management strategies, and provide blood samples duri…
Sponsor: Royal United Hospitals Bath NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
MS drug use in pregnancy under the microscope: is it safe for baby?
Knowledge-focused OngoingThis study looks at how many women with multiple sclerosis (MS) use the drug interferon-beta during the second and third trimesters of pregnancy in Finland and Sweden. Researchers want to know if there are enough cases to study whether the drug affects pregnancy outcomes like bir…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Can a blood test predict lupus flares? new study aims to find out
Knowledge-focused OngoingThis study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…
Phase 3 • Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Scientists probe immune secrets of four skin diseases
Knowledge-focused By invitation onlyThis study aims to understand inflammation in four chronic skin conditions: vitiligo, psoriasis, eczema (atopic dermatitis), and alopecia areata. Researchers will collect blood and small skin samples from 450 adults to analyze immune cells called T-cells. The goal is to describe …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to see if patient diaries match insurance data
Knowledge-focused CancelledThis study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists hunt for clues to predict blistering disease severity
Knowledge-focused OngoingThis study looks at 50 people with bullous pemphigoid, a skin condition that causes blisters. Researchers want to see if certain proteins in skin samples and blood markers like IgE and eosinophil counts are linked to how severe the disease is. The goal is to find better ways to m…
Sponsor: Istanbul Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test could predict MS Flare-Ups, study hopes
Knowledge-focused OngoingThis study looks at whether a blood test measuring a protein called neurofilament light (sNfL) can help doctors predict and manage disease activity in people with relapsing multiple sclerosis (MS). About 489 adults with MS in Germany will be observed for 24 months. The goal is to…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Gut check: 4,000-Person study links diet, genes, and stomach troubles
Knowledge-focused By invitation onlyThis study looks at how diet, genetics, and gut bacteria work together to cause digestive problems like IBS, IBD, and celiac disease. Researchers will follow about 4,000 adults with and without these conditions to find patterns. The goal is to understand why some people get sick …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Massive italian MS registry aims to unlock secrets of the disease
Knowledge-focused By invitation onlyThis observational study is creating a large database of up to 96,000 people with multiple sclerosis and related conditions in Italy. Researchers will collect information on patient demographics, treatments, and disease progression over time. The goal is to better understand thes…
Sponsor: Fondazione Italiana Sclerosi Multipla • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Brain scans may predict who gets long-term pain from arthritis
Knowledge-focused OngoingThis study looks at why some people with early rheumatoid arthritis develop long-lasting chronic pain while others do not. Researchers will use pain sensitivity tests and brain scans to find clues. The goal is to better understand the transition from acute to chronic pain, which …
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New MRI study seeks hidden stroke causes in rare blood disorder
Knowledge-focused By invitation onlyThis study looks at why people with antiphospholipid syndrome (APS) — a condition that raises blood clot risk — may have narrowed brain arteries. Researchers will use advanced MRI scans on 60 APS patients to check for artery narrowing and plaque buildup. The goal is to better und…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
New study probes why kidney disease still strikes in type 1 diabetes
Knowledge-focused OngoingThis study looks at why up to 40% of people with type 1 diabetes develop kidney disease, even with better blood sugar control. Researchers will use kidney biopsies and advanced imaging in 100 adults to find hidden risk factors like insulin resistance and inflammation. The goal is…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Researchers hunt for clues: do our own antibodies harm nerves?
Knowledge-focused By invitation onlyThis study looks at whether the immune system mistakenly makes antibodies that attack the body's own nerves and muscles in people with multiple sclerosis, myasthenia gravis, and similar conditions. Researchers will collect blood samples (and sometimes cheek swabs) from 120 adults…
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Does an extra knee ligament procedure lead to arthritis later?
Knowledge-focused By invitation onlyThis study follows 510 people who had ACL knee reconstruction surgery, with or without an extra procedure called LET, about 10 years ago. Researchers want to see if adding LET increases the chance of developing knee osteoarthritis. Participants will get X-rays and answer question…
Sponsor: Western University, Canada • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
AI listens to your voice to spot diabetes stress
Knowledge-focused PausedThis study explores whether artificial intelligence can detect stress in people with type 1 diabetes by analyzing their voice recordings. Participants record their voice four times a day for a period. The goal is to develop a tool that helps patients and doctors better understand…
Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New registry aims to unlock safer pregnancies for women with autoimmune conditions
Knowledge-focused By invitation onlyThis registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Smartphone app tracks stress to uncover diabetes blood sugar mystery
Knowledge-focused PausedThis study looks at how everyday stress impacts blood sugar levels in people with type 1 diabetes. Researchers will ask 125 participants to rate their stress four times a day using a smartphone app, while a continuous glucose monitor tracks their blood sugar. The goal is to see i…
Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Tiny study peers inside finger joints to unlock RA bone erosion secrets
Knowledge-focused OngoingThis study looks at bone erosions in the finger joints of 9 people with rheumatoid arthritis. Researchers use advanced imaging and tissue analysis to see tiny blood vessels and bone structure. The goal is to better understand how joint damage happens, which could lead to better m…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Sjögren's study dives deep into immune clues in spit and blood
Knowledge-focused OngoingThis study looks at immune system markers in the saliva and blood of 80 people with primary Sjögren's syndrome, a chronic disease causing dry eyes and mouth. Researchers will check for antibodies that may block a key enzyme and see how gum disease affects symptoms. The goal is to…
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New hip cup under observation: will it last?
Knowledge-focused OngoingThis study is observing 60 people who received a special hip replacement cup (Plasmafit Revision Structan) during routine surgery. Researchers are checking how well the cup works and how long it lasts by tracking hip function and any need for repeat surgery. No new treatment is b…
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scleroderma biomarker study pulled before start
Knowledge-focused CancelledThis study planned to collect extra blood and urine samples from scleroderma patients during their regular check-ups to find biological markers that could predict if their disease would get worse over the next 10 years. The goal was to improve treatment decisions and identify the…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can online chats help latinx teens master diabetes tech?
Knowledge-focused OngoingThis study tests whether virtual peer groups can help Latinx teenagers with type 1 diabetes use insulin pumps and continuous glucose monitors more effectively. About 120 teens and their caregivers will join online sessions covering topics like family relationships, school, and wo…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
French study tracks daily life changes in MS patients on newer drug
Knowledge-focused OngoingThis study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world be…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New study sheds light on thyroid disease in kids under 6
Knowledge-focused By invitation onlyThis study examines autoimmune hyperthyroidism in children diagnosed before age 6, focusing on their symptoms, growth, and response to treatment. Researchers will compare these young children with older children who have the same condition. The goal is to identify patterns that c…
Sponsor: IRCCS Ospedale San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry aims to unlock secrets of rare blood disorder
Knowledge-focused OngoingThis study is a registry that collects information from about 429 adults with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS), a rare condition where the immune system attacks red blood cells in cold temperatures. Researchers will track symptoms, treatments, compl…
Sponsor: RECORDATI GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Virtual reality vs. slideshow: which teaches nursing students more about MS?
Knowledge-focused OngoingThis study tested two teaching methods for nursing students: a 360-degree video experience about the brain and multiple sclerosis (MS), and a standard slideshow with the same information. About 50 students from three nursing schools took part. Researchers measured how much they l…
Sponsor: Hunter College of City University of New York • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:10 UTC
-
New study observes patients getting nasal stem cell therapy for brain conditions
Knowledge-focused By invitation onlyThis observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…
Sponsor: Healing Hope International • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
MS app study pulled before it even started
Knowledge-focused CancelledThis study aimed to test whether a smartphone app could track multiple sclerosis (MS) symptoms and progression remotely. It planned to enroll adults with MS across different countries to see if digital measurements matched standard clinical tests. However, the study was withdrawn…
Sponsor: Research Center for Clinical Neuroimmunology and Neuroscience Basel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Scientists hunt for hidden clues in adult diabetes
Knowledge-focused OngoingThis study aims to find new biological markers (biomarkers) for Adult Onset Autoimmune Diabetes (AOnAD) by analyzing blood samples from 25 adults with type 1 diabetes. Researchers will measure changes in specific microRNAs from tiny particles in the blood. No treatment is given; …
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Rare disease pregnancy study pulled before it began
Knowledge-focused CancelledThis study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Tiny study probes why MS drug may miss hidden immune cells
Knowledge-focused By invitation onlyThis study will examine lymph nodes from 5 people with relapsing-remitting multiple sclerosis who are starting ocrelizumab treatment. The goal is to see how effectively the drug removes B cells from lymph nodes, since these cells are known to be important in MS but are not well s…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Study aims to boost diabetes tech access for underserved kids
Knowledge-focused CancelledThis study was designed to learn why some children with type 1 diabetes, especially those with public insurance, do not use helpful diabetes technology like continuous glucose monitors. Researchers planned to interview and survey healthcare providers to understand barriers and fi…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Walking study for Parkinson's and stroke patients withdrawn before starting
Knowledge-focused CancelledThis study was designed to test a wearable sensor system that tracks how people walk on different surfaces like grass, pavement, and stairs. It aimed to include healthy volunteers and people with conditions such as Parkinson's disease, dementia, stroke, multiple sclerosis, or low…
Sponsor: University of Leeds • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
15,000 skin patients enrolled in massive Real-World treatment study
Knowledge-focused OngoingThis study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Massive diabetes biobank aims to predict kidney and heart risks
Knowledge-focused OngoingThis study is building a large biobank of health information and blood samples from 48,000 people with diabetes in Hong Kong. Researchers will analyze genetic and other markers to find better ways to predict serious complications like kidney failure, heart disease, and stroke. Th…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Scientists hunt for clues to MS severity
Knowledge-focused OngoingThis study aims to find a combination of markers—from genetics, immune system, and brain scans—that are linked to how severe multiple sclerosis (MS) becomes. Researchers will follow 120 people with MS and their siblings who also have the condition. Participants undergo neurologic…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Pregnancy and diabetes: new study tracks insulin changes
Knowledge-focused By invitation onlyThis study aims to understand how the body's response to insulin changes during pregnancy in people with type 1 diabetes. Researchers will analyze data from continuous glucose monitors and insulin pumps used by 100 participants from before pregnancy to six months after birth. The…
Sponsor: University of Virginia • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Fatty liver and psoriasis study pulled before it started
Knowledge-focused CancelledThis study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the t…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Soccer field showdown: diabetic vs healthy Boys' bodies put to the test
Knowledge-focused By invitation onlyThis study looks at differences in body composition, fitness, and temperature control during exercise between young soccer players with type 1 diabetes and healthy ones. Forty boys who have trained for at least 5 years will be monitored with thermal cameras and continuous glucose…
Sponsor: Paweł Korman • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Diabetes heart study pulled before it even started
Knowledge-focused CancelledThis study aimed to learn more about using a CT scan to check for calcium buildup in the heart arteries of people with diabetes. The goal was to improve screening and treatment decisions. However, the study was withdrawn before enrolling any participants, so no new information wa…
Sponsor: French Cardiology Society • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Lupus heart risk: new study seeks better prediction tools
Knowledge-focused OngoingThis study looks at 500 adults with lupus to see if certain immune markers can better predict who will develop heart disease. Participants give blood samples, have ultrasound scans of their neck arteries, and fill out diet and exercise questionnaires. The goal is to improve how d…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a heart scan save lives in rheumatoid arthritis? major study aims to find out
Knowledge-focused By invitation onlyThis study will use advanced heart scans (coronary CT angiography) on 4,000 people with rheumatoid arthritis aged 50-75. The goal is to better understand why people with this condition have higher risks of heart attacks, strokes, and lung problems. Researchers will track particip…
Sponsor: Ellen Margrethe Hauge • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can virtual MS care match in-person visits? new study aims to find out.
Knowledge-focused OngoingThis study compares virtual (telehealth) care to standard in-person visits for 120 adults recently diagnosed with multiple sclerosis. The goal is to see if virtual care can prevent disability progression just as well, while also being more convenient and cost-effective. Participa…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
1,200-Patient study aims to predict liver failure risks
Knowledge-focused OngoingThis observational study follows 1,222 adults with liver cirrhosis to understand why some develop serious complications like fluid buildup or bleeding. Participants have check-ups every six months, including questionnaires, physical exams, and imaging. The goal is to build better…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Join the brain health registry and help fight Alzheimer's from home
Knowledge-focused By invitation onlyThe Brain Health Registry is an online project that collects information about memory, mood, sleep, diet, and exercise from adults over 18. Participants also take simple cognitive tests online. The goal is to build a large database to speed up research into brain diseases like Al…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused PausedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Does starting MS drug early make a difference? austrian study aims to find out
Knowledge-focused OngoingThis study observes 106 Austrian patients with relapsing multiple sclerosis who are already taking Ofatumumab (Kesimpta). Researchers compare those who started the drug early versus later, tracking disease activity over two years. The goal is to see if early treatment leads to fe…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Unlocking healthy aging secrets for type 1 diabetes
Knowledge-focused By invitation onlyThis study follows 400 adults aged 65 and older with type 1 diabetes to understand how they age compared to people without diabetes. Researchers will measure physical ability, thinking skills, and emotional well-being. The goal is to learn what helps some people age well despite …
Sponsor: Helsinki University Central Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Biking for science: could AI predict blood sugar spikes during exercise?
Knowledge-focused OngoingThis study asks 29 adults with type 1 diabetes to complete a 75 km gravel bike ride while wearing a continuous glucose monitor and providing saliva and urine samples. Researchers want to collect detailed data to help build artificial intelligence models that can predict how exerc…
Sponsor: Universitat de Girona • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
AI brain scans could revolutionize MS care
Knowledge-focused By invitation onlyThis study looks at whether using an AI tool to analyze brain MRIs helps doctors spot signs of multiple sclerosis (MS) activity more accurately. About 750 people with MS or early warning signs will be split into two groups: one where doctors use the AI tool, and one where they re…
Sponsor: icometrix • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Can combining mental and physical tasks boost brain rehab?
Knowledge-focused OngoingThis study is testing whether rehabilitation that combines physical and mental exercises (called dual-task training) can help people with stroke, multiple sclerosis, Parkinson's disease, or long COVID. Researchers will design and try out different dual-task strategies in small gr…
Sponsor: I.R.C.C.S. Fondazione Santa Lucia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Can a smartphone app cut down doctor visits for arthritis patients?
Knowledge-focused OngoingThis study tests whether a smartphone app can help people with psoriatic arthritis manage their condition with fewer in-person doctor visits. About 278 adults who already use certain arthritis medications will use the app to report symptoms. Researchers will compare visit frequen…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Navigator plus tech aims to close diabetes care gap
Knowledge-focused OngoingThis study tests whether a Patient Navigator can help 150 people with type 1 diabetes use their continuous glucose monitors more effectively. The goal is to reduce health disparities and improve outcomes. Participants will receive extra support while using their standard CGM devi…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New glucose monitor could make skies safer for diabetic pilots
Knowledge-focused OngoingThis study looks at whether a continuous glucose monitor (Dexcom G6) helps pilots with insulin-treated diabetes keep their blood sugar in a safe range during flights. Seventeen pilots wore the device for six months, comparing its readings with their usual finger-stick tests. The …
Sponsor: University of Surrey • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Gut leak link to Sjögren's Flare-Ups under microscope
Knowledge-focused OngoingThis study looks at whether changes in gut bacteria can affect Sjögren's syndrome, an autoimmune disease causing dry eyes, dry mouth, and fatigue. Researchers will measure blood markers of gut leakage in 50 adults with Sjögren's to see if these markers change when disease activit…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New MRI scans aim to unlock secrets of the pancreas in type 1 diabetes
Knowledge-focused By invitation onlyThis study uses advanced MRI scans to measure the size and texture of the pancreas in people recently diagnosed with type 1 diabetes. Researchers hope to develop standard methods for assessing the pancreas, which could improve understanding of the disease. About 250 participants …
Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Massive MS registry study probes Long-Term safety of common drugs
Knowledge-focused OngoingThis study looks at the long-term safety of two multiple sclerosis (MS) medications, Vumerity and Tecfidera, by analyzing data from over 10,000 patients in large MS registries. The goal is to track serious side effects, including infections and cancer, and compare them to other M…
Sponsor: Biogen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New study tests if help with housing, food, or transport can cut missed arthritis appointments
Knowledge-focused OngoingThis study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
App aims to help parents of kids with diabetes, but study was withdrawn
Knowledge-focused CancelledThis study was designed to find out what parents of children aged 8-12 with type 1 diabetes need to better use insulin pumps and continuous glucose monitors. Researchers planned to use this information to create an app to support parents and improve diabetes management. However, …
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Biopsy-Guided arthritis treatment: a step toward personalized care?
Knowledge-focused CancelledThis study aimed to see if analyzing joint tissue (synovial biopsies) could help doctors pick the best biologic drug for people with rheumatoid arthritis who had not responded to standard treatments. It planned to assign patients to either an anti-TNF or a JAK inhibitor based on …
Phase 3 • Sponsor: Abu Dhabi Stem Cells Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Thyroid Surgery's heart impact study pulled before start
Knowledge-focused CancelledThis study aimed to see if thyroid surgery changes the thickness of the carotid artery, which is a sign of heart disease risk. It planned to measure artery thickness before and after surgery in adults with various thyroid conditions. However, the study was withdrawn before enroll…
Sponsor: Istituto Auxologico Italiano • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Can an app improve MS care? new study tests MSCopilot flower
Knowledge-focused OngoingThis study looks at how well the MSCopilot Flower app works for people with multiple sclerosis. The app includes tests for walking, thinking, hand use, and vision, plus questionnaires about fatigue and anxiety. Researchers want to see if patients can use it easily at home and if …
Sponsor: Ad scientiam • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Hidden eating disorders may sabotage new diabetes tech
Knowledge-focused OngoingThis study looks at how common eating disorders are in people with type 1 diabetes who are starting a new automated insulin pump (closed-loop therapy). Researchers want to see if these eating problems, like skipping insulin to lose weight, make it harder to control blood sugar. A…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
1,598 RA patients enrolled in quest to personalize treatment
Knowledge-focused OngoingThis study follows 1,598 adults with rheumatoid arthritis (RA) over time to identify biological markers that can predict how well a patient will respond to a drug or whether they might have side effects. Researchers also aim to understand how the disease progresses and affects da…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Weighty questions: how obesity affects arthritis drug dosing
Knowledge-focused CancelledThis study aimed to understand how body weight influences the way etanercept works in obese adults and children with arthritis. Researchers planned to use blood samples and computer models to find the best dose for heavier patients. However, the study was withdrawn before enrolli…
Phase 1 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
MS brain scan study aims to spot progression risk early
Knowledge-focused OngoingThis study looks at whether special brain scans can detect signs of worsening in people with multiple sclerosis (MS). Researchers will scan 35 patients aged 40-50 who have had MS for at least five years. They are measuring brain cell activity that may signal disease progression. …
Sponsor: Turku University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Brain immune activity may predict MS lesion growth over 10 years
Knowledge-focused By invitation onlyThis study follows 100 people with multiple sclerosis to see if increased activity of certain brain immune cells (microglia) around lesion edges is linked to faster lesion growth over 10 years. Participants had a special PET scan at the start and will have follow-up MRI scans. Th…
Sponsor: Turku University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New algorithm aims to catch ovarian damage early in young cancer survivors
Knowledge-focused CancelledThis study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
Does diabetes affect the brain? new study investigates thinking and emotions in youth with type 1 diabetes
Knowledge-focused By invitation onlyResearchers in India are studying how type 1 diabetes affects thinking, memory, and mental health in children and young adults aged 10 to 21. They will compare 264 youth with type 1 diabetes to 132 healthy peers using tests of intelligence, attention, memory, and emotional well-b…
Sponsor: Hirabai Cowasji Jehangir Medical Research Institute • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:03 UTC
-
Biosimilar arthritis drug under Real-World watch
Knowledge-focused OngoingThis study follows 600 people with moderate to severe rheumatoid arthritis who are prescribed Tyenne, a biosimilar of tocilizumab. Researchers will track how long patients stay on the treatment over 12 months. The goal is to see how well the drug works in everyday medical practic…
Sponsor: Fresenius Kabi SwissBioSim GmbH • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:58 UTC
-
Can a simple training program help teachers manage diabetes emergencies?
Knowledge-focused OngoingThis study tests a structured educational program for teachers and kindergarten staff to improve their knowledge and attitudes about caring for children with type 1 diabetes. About 100 educational staff will take part, answering questionnaires before, right after, and three month…
Sponsor: Sibenik University of Applied Sciences • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:21 UTC